Clinical Development  
Ribociclib (LEE011) 
Oncology Clinical Protocol CLEE011G2301 (EarLEE-1) / [STUDY_ID_REMOVED]
An open label, multi-center protocol for U.S. patients enrolled in 
a study of ribociclib with endocrine therapy as an adjuvant 
treatment 
in patients with hormone receptor-positive, HER2-
negative, high risk early breast cancer 
Authors   
 
Docu ment type  Amended Protocol Version  
EUDRACT number  2014 -001795 -53 
Version number  02 (Clean ) 
Development phase  II 
Document status  Final  
Release date  17-Apr-2018
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published or otherwise disclosed  
without the consent of [COMPANY_001]  
Template version 22-Jul-2016 

[COMPANY_001]  Confidential  Page 2 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Table of contents  
Table of contents  ................................ ................................ ................................ .................  [ADDRESS_432765] of abbreviations  ................................ ................................ ................................ ............  6 
Glossary of terms  ................................ ................................ ................................ .................  9 
Protocol summary  ................................ ................................ ................................ ..............  10 
Amendment 2 (17 -Apr-2018)  ................................ ................................ ............................  14 
Amendment 1 (21 -Jun-2017)  ................................ ................................ ............................  17 
1 Background  ................................ ................................ ................................ ........................  19 
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_013]  ..............  19 
1.1.1  Epi[INVESTIGATOR_623]  ................................ ................................ ........................  19 
1.1.2  Treatment of EBC  ................................ ................................ .................  19 
1.1.3  Role of the CDK4/[ADDRESS_432766] in BC  ................................ .....................  21 
1.2 Introduction to investigational treatments and other study treatments  ..................  22 
1.2.1  Overview of ribociclib  ................................ ................................ ..........  22 
1.2.2  Overview of adjuvant endocrine therapy  ................................ ..............  25 
2 Rationale  ................................ ................................ ................................ ............................  27 
2.1 Study rationale and purpose  ................................ ................................ ...................  27 
2.2 Rationale for the study design  ................................ ................................ ...............  28 
2.3 Rationale for dose and regimen selection  ................................ ..............................  30 
2.4 Rationale for choice of combination drugs  ................................ ............................  30 
2.5 Rationale for choice of comparators drugs  ................................ ............................  30 
2.6 Risks and ben efits ................................ ................................ ................................ .. 30 
3 Objectives and endpoints  ................................ ................................ ................................ ... 31 
4 Study design  ................................ ................................ ................................ ......................  31 
4.1 Description of study design  ................................ ................................ ...................  31 
4.1.1  Screening phase  ................................ ................................ .....................  32 
4.1.2  Treatment phase  ................................ ................................ ....................  32 
4.1.3  Follow up phase  ................................ ................................ ....................  33 
4.2 Definition of end of study  ................................ ................................ ......................  33 
4.3 Early study termination  ................................ ................................ ..........................  34 
5 Population  ................................ ................................ ................................ ..........................  34 
5.1 Patient population  ................................ ................................ ................................ .. 34 
5.2 Inclusion criteria  ................................ ................................ ................................ .... 34 
5.3 Exclusion criteria  ................................ ................................ ................................ ... 37 
6 Treatment  ................................ ................................ ................................ ...........................  39 
[COMPANY_001]  Confidential  Page 3 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 6.[ADDRESS_432767] to f ollow-up ................................ ................................ ...................  63 
7.2 Assessment types  ................................ ................................ ................................ ... 63 
7.2.1  Recurrence assessments  ................................ ................................ ........  63 
7.2.2  Safety and tolerability assessments  ................................ .......................  64 
7.2.3  Biomarkers  ................................ ................................ ............................  68 
7.2.4  Resource utilization  ................................ ................................ ...............  68 
7.2.5  Patient reported outcomes  ................................ ................................ ..... 68 
8 Safety monitoring and reporting  ................................ ................................ ........................  68 
[COMPANY_001]  Confidential  Page 4 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 8.[ADDRESS_432768]  ................................ .........................  70 
8.2 Serious adverse events  ................................ ................................ ...........................  70 
8.2.1  Definitions  ................................ ................................ .............................  70 
8.2.2  Reporting  ................................ ................................ ...............................  71 
8.3 Emergency unblinding of treatment assignment  ................................ ...................  71 
8.4 Pregnancies  ................................ ................................ ................................ ............  72 
8.5 Warnings and precautions  ................................ ................................ ......................  72 
8.6 Data Monitoring Committee  ................................ ................................ ..................  72 
8.7 Steering Committee  ................................ ................................ ...............................  72 
9 Data collection and management  ................................ ................................ .......................  72 
9.1 Data confidentiality  ................................ ................................ ...............................  72 
9.2 Site monitoring  ................................ ................................ ................................ ...... 73 
9.3 Data collection  ................................ ................................ ................................ ....... 73 
9.4 Database management and quality control  ................................ ............................  74 
10 Statistical methods and data analysis  ................................ ................................ ................  75 
10.1  Interim analysis  ................................ ................................ ................................ ...... 75 
10.2  Sample size calculation  ................................ ................................ ..........................  75 
11 Ethical considerations and administrative procedures  ................................ ......................  75 
11.1  Regulatory and ethical compliance  ................................ ................................ ........  75 
11.2  Responsibilities of the inve stigator and IRB/IEC/REB  ................................ .........  [ADDRESS_432769] keepi[INVESTIGATOR_348378]  .......................  77 
11.7  Confidentiality of study documents and patient records  ................................ ....... 78 
11.8  Audits and inspections  ................................ ................................ ...........................  78 
11.9  Financial disclosures  ................................ ................................ ..............................  78 
12 Protocol  adherence  ................................ ................................ ................................ ............  78 
12.1  Amendments to the protocol  ................................ ................................ ..................  78 
13 References (available upon request)  ................................ ................................ ..................  80 
14 Appendices  ................................ ................................ ................................ ........................  84 
14.1  Appendix 1: Guidelines for Anatomic and Prognostic Stage Group III of HR -
positive, HER2 -negative Breast Cancer for breast cancer staging (based on 
AJCC Ed. 8th) ................................ ................................ ................................ .........  84 
[COMPANY_001]  Confidential  Page 5 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 14.2  Appendix 2: Concomitant medications  ................................ ................................ . [ADDRESS_432770] of tables  
Table 3 -1 Objectives and related endpoints  ................................ ..........................  31 
Table 6 -1 Dose and treatment schedule  ................................ ................................ . 40 
Table 6 -2 Dose modification guidelines  ................................ ................................  42 
Table 6 -3 Ribociclib dose adjustment and management rec ommendations for 
hematological adverse reactions  ................................ ...........................  43 
Table 6 -4 Ribociclib dose adjustment and management recommendation for 
hepatic toxicities  ................................ ................................ ....................  44 
Table 6 -5 Ribociclib dose adjustment and management recommendation for 
QTcF prolongation  ................................ ................................ ................  45 
Table 6 -6 Ribociclib dose adjustment and management recommendation for 
all other adverse reactions  ................................ ................................ ..... 46 
Table 6 -7 Packaging and labeling  ................................ ................................ .........  53 
Table 6 -8 Supply and storage of study treatments  ................................ ................  53 
Table 7 -1 Visit evaluation schedule  ................................ ................................ ...... 55 
Table 7 -2 Clinical laboratory parameter s collection plan (all are done locally 
with the protocol amendment 02)  ................................ .........................  65 
Table 7 -3 Local clinical laboratory parameters assessment plan  ..........................  67 
Table 7 -4 ECG collection plan (all ECGs are performed and assessed locally 
with the protocol amendment 02)  ................................ .........................  67 
Table 14 -1 AJCC 8th edition Anatomic Stage Groups (not including Group IV 
- all M -category M0)  ................................ ................................ .............  [ADDRESS_432771] Cancer (all M -category M0)  ............................  [ADDRESS_432772] of medications to be used with caution during study drug 
treatment  ................................ ................................ ................................  87 
 
[COMPANY_001]  Confidential  Page 6 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 List of abbreviations  
AE Adverse Event  
AESI  Adverse events of special interest  
AI Aromatase inhibitor  
AJCC  American Joint Committee on Cancer  
ALND  Axillary lymph node dissection  
ALP Alkaline Phosphatases  
ALT Alanine  aminotransferase/glutamic pyruvic transaminase/GPT  
ANC  Absolutely Neutrophil Count  
ASCO  American Society of Clinical Oncology  
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT  
AUC  Area Under the Curve  
BC Breast cancer  
BCRP  Breast cancer resistance protein  
BSEP  Bile salt export pump  
BUN  Blood Urea Nitrogen  
CABG  coronary artery by[CONTACT_348403]1  Cyclin D1  
CDK  Cyclin -Dependent Kinase  
CI Confidence Interval  
Cmax  Maximum Concentration  
CMO&PS  Chief Medical Office and Patient Safety  
CMV  Cytomegalovirus  
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper  
CRO  Contract Research Organization  
CSR  Clinical study report  
CSR addendum  An addendum to Clinical Study Report (CSR) that captures all the additional information 
that is not included in the CSR  
CT Computed Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
ctDNA  Circulating tumor DNA  
CV Coefficient of variation  
CYP Cytochrome P450  
DDFS  Distant disease free survival  
DDI Drug -Drug Interaction  
DHEA  dehydroepi[INVESTIGATOR_348379] -Induced Liver Injury  
DNA  Deoxyribonucleic Acid  
DS&E  Drug Safety and Epi[INVESTIGATOR_348380] -specific survival  
EBC Early Breast Cancer  
EBCTCG  EBC Trialists’ Collaborative Group  
EBV Epstein -Barr Virus  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
[COMPANY_001]  Confidential  Page 7 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case Report/Record Form  
eGFR  Estimated glomerular filtration rate  
EOT End of Treatment  
ER Estrogen receptor  
ET Endocrine Therapy  
FISH  Fluorescence in situ hybridization  
FMO3  flavin -containing monooxygenase 3  
FSH Follicle -stimulating hormone  
GGT  Gamma -glutamyl transferase  
GI Gastrointestinal  
GnRH  Gonadotropin -releasing hormone  
HADS  Hospi[INVESTIGATOR_348381] B virus  
hCG human chorionic gonadotropin  
HCV  Hepatitis C virus  
HER2 - Human epi[INVESTIGATOR_3506] 2 negative  
HR Hormone Receptor  
HR positive  Hormone Receptor positive  
HSV Herpes Simplex Virus  
i.v. intravenous(ly)  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
iDFS  Invasive disease -free survival  
IEC Independent Ethics Committee  
IHC Immunohistochemistry  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive Web Response System  
IUD Intrauterine device  
LDH Lactate dehydrogenase  
LFT Liver Function Test  
LRRFS  Loco -regional recurrence -free survival  
LVEF  Left Ventricular Ejection Fraction  
MATE1  multidrug and toxin extrusion protein -1 
MI Myocardial infection  
MRI Magnetic Resonance Imaging  
MUGA  Multiple Gated acquisition  
NaF-PET Sodium fluoride positron emission tomography  
NASH  Non-alcoholic fatty liver disease  
NCI National Cancer Institute  
OCT2  Organic cation transporter 2  
OS Overall survival  
p.o. per os/by [CONTACT_1966]/orally  
PFS Progression -free survival  
P-gp P-glycoprotein  
[COMPANY_001]  Confidential  Page 8 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 PgR Progesterone Receptor  
PHI Protected Health Information  
PK Pharmacokinetics  
PRO  Patient Reported Outcome  
PT Prothrombin time  
PVCs  Premature ventricular contractions  
QTcF  Q-T interval in the ECG (corrected according to the formula of Fridericia)  
Rb Retinoblastoma protein  
RBC  Red Blood Cells  
REB Research Ethics Board  
RFS Recurrence free survival  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SBP Systolic Blood Pressure  
SEER  Surveillance, Epi[INVESTIGATOR_623], and End Results Program  
SISH  Silver in situ Hybridization  
SLN Sentinel lymph node  
SOP  Standard Operating Procedure  
TBIL  Total Bilirubin  
TdP Torsades de Pointe  
Tmax  The time at which the maximum observed concentration (Cmax) occurs  
ULN Upper Limit of Normal  
WBC  White blood cell count  
[COMPANY_001]  Confidential  Page 9 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Glossary of terms  
Assessment  A procedure used to generate data required by [CONTACT_217924] A biological speci men including, for ex ample, blood  (plas ma, serum), saliva, tissue,  
urine, stool,  etc. t aken fr om a study s ubject or  study patient  
Control drug  A study treatment used as a comparator to reduce assessment bias, preserve blinding 
of investigational drug, assess internal study validity, and/or evaluate comparative 
effects of the investigational drug  
Cycles  Number and timing or recommended repetitions of therapy are usually expressed as 
number of days (e.g.: 28 days)  
Dose level  The dose of drug given to the patient ( e.g. total daily)  
Enrollment  Point/time of patient entry into the study; the point at which informed consent must be 
obtained (i.e. prior to starting any of the procedures d escribed in the protocol)  
Investigational drug  The study treatment whose properties are being tested in the study; this definition is 
consistent with US A Code of Federal Regulations ( CFR) 21 Section 312.3 and is 
synonymous with “investigational new drug”  
Investigational 
treatment  Drug whose properties are being tested in the study as well as their associated placebo 
and active treatment controls (when applicable). This also includes approved drugs 
used outside of their indication/approved dosage, or that are tested in a fixed 
combination. Investigational treatment generally does not include other study 
treatments administered as concomitant background therapy required or allowed by [CONTACT_348404]/dosage  
Medication num ber A unique identifier on the label of each study treatment package which is linked to one 
of the treatment groups of a study  
Other study treatment  Any drug administered to the patient as part of the required study procedures that was 
not included in the  investigational treatment  
Subject Number 
(Subject No.)  A unique identifying number assigned to each patient/subject/healthy volunteer who 
enrolls in the study  
Phase  A subdivision of the study timeline; divides stages into smaller functional segments 
such as screening, treatment , follow up  
Randomization number  A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm /group  assignment  
Stage related to study 
timeline  A major subdivision of the study timeline; begins and ends with major study milestones 
such as enrollment, randomization, completion of treatment, etc  
Stage in cancer  The extent of a cancer in the body. Staging is usually based on the size of the tumor, 
whether lymph nodes contain cancer, and whether the cancer has spread from the 
original site to other parts of the body  
Stop study participation  Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued whichever is later  
Study tr eatment  Includes any drug or combination of drugs in any study arm administered to the patient 
(subject) as part of the required study procedures, including placebo and active drug 
run-ins. 
In specific examples, it is important to judge investigational tre atment component 
relationship relative to a study treatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combination  
Study treatment 
discontinuation  Point/time when patient permanently stops  taking study treatment for any reason  
Treatment group  A treatment group defines the dose and regimen or the combination.  
Variable  Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified time  points  
Withdrawal of consent Withdrawal of co nsent occurs only wh en a patient d oes not want to partic ipate in  the 
study any  longer, a nd does not want  any further visits or assessmen ts, and  does not 
want any further study related cont act 
[COMPANY_001]  Confidential  Page 10 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Protocol summary  
Title An open label, multi -center protocol for U.S. patients enrolled  in a study of ribociclib 
with endocrine therapy as an adjuvant treatment in patients with hormone receptor -
positive, HER2 -negative, high risk early breast cancer  
Brief title A protocol for U.S. patients enrolled in a s tudy of ribociclib with endocrine therapy 
in patients with hormone receptor -positive, HER2 -negative, high risk early breast 
cancer . 
Sponsor and  
Clinical Phase  [COMPANY_001]  
Phase II  
Investigation type  Drug  
Study type  Interventional  
Purpose and rationale  While adjuvant endocrine therapy (ET) is effective in reducing risk of recurrence in 
patients with hormone receptor (HR) -positive early breast cancer (EBC), 
recurrences are still common, especially in patien ts with unfavorable clinical, 
pathological and/or molecular features. Ribociclib, a CDK4/[ADDRESS_432773] the safety data  on the combination of 
ribociclib + ET in  HR+, HER2 -negative high –risk EBC patients who enrolled in this 
study prior to th e early closure of enrollment on 1 2 Feb 2018.Patients were 
randomized in the US  only. All randomized patients were unblinded; patients 
randomized to placebo permanently discontinued study treatment and patients 
randomized to ribociclib were offered the option to continue treatment with 
ribociclib + ET (excluding tamoxifen) for 2 6 cycles of ribociclib.  
Primary Objective(s) and 
Key Secondary Objective  Primary :  
The main objective of the study is to evaluate the preliminary safety and tolerability 
of the ribociclib + ET  in patients that were r andomized to ribociclib + ET  prior to the 
early closure of enrollment . 
Key secondary : none  
Secondary Objectives  None  
Study design  This was a randomized, phase III, double -blind, placebo -controlled, multi -center, 
international study to evaluate efficacy and safety of ribociclib with ET as an 
adjuvant treatment in patients with HR -positive, HER2 -negative high risk EBC.   
Following the  early  closure of enrollment and the protocol amendment 02, the  
study will change to a phase II study  conducted  in the US only .  
It will include :  
● Screening phase where written informed consent will be collected and all 
eligibility criteria verified (28 days)  – this phase has been completed for all patients 
as of 12 February 2018 ; 
● Treatment phase : Ribociclib patients were randomized receive ribociclib [ADDRESS_432774] adjuvant ET.  With the early closure of enrollment,  all patients were 
unblinded. P atients randomized to placebo + ET permanently discontinued study 
treatment after unblinding.  
After unblinding,  patients  randomized to ribociclib will receive ribociclib + ET 
treatment for a maximum of 26 cycles (approximately 24 months) or until first 
disease recurrence, intolerable toxicity, withdrawal of consent, death or 
discontinuation from the study treatment for any oth er reason, whichever is earlier  
ET may start up to 12 weeks before t he date of randomization . ET includes orally 
administered , letrozole, anastrozole, or exemestane. In premenopausal women the 
ET will include GnRH agonists (such as goserelin, triptorelin or leuprolide .) 
(Tamoxifen is not permitted as an ET combination part ner as of 17 Feb 2018). ET 
should not be changed during treatment with ribociclib unless intolerable toxicity, 
patient’s request, or any other medically -important event that requires change of 
ET.  
Patients will have safety and recurrence assessments while  on ribociclib therapy 
[COMPANY_001]  Confidential  Page 11 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 as per protocol.  
All patients, regardless of the reason for treatment discontinuation (except death) 
will be followed for safety for [ADDRESS_432775] dose of ribociclib  
● Follow up phase  
With the protocol amendment 02, follow -up phase assessments are no longer 
performed.  
● For each patient randomized to placebo + ET, study participation will end 
following the safety follow -up after the last dose of placebo.  
● For each patient randomized to ribociclib + ET, study participation will end 
following the safety follow up after the last dose of ribociclib.   
● Patients who are during their follow -up phase assessments at the time of the 
protocol amendment [ADDRESS_432776] undergone the safety follow -up 30 days after the end of treatment (EOT). The 
study is expected to continue for approximately [ADDRESS_432777] patient 
randomized  to ribociclib completed an end of treatment safety follow -up.   
Population  The study will include pre - and postmenopausal women with HR -positive, HER2 -
negative high risk EBC after adequate surgical resection, radiotherapy (if 
indicated), adjuvant or neo -adjuvant chemotherapy, and who are deemed to be 
eligible for adjuvant ET for at least [ADDRESS_432778] ensure that only patients who meet all of the following inclusion and 
none of the exclusion criteria are offered treatment in the study.  
Key Inclusion criteria  No changes were made to the eligibility criteria  since all patients were randomized 
prior to the closure of enrollment and the release of the protocol amendment 02.  
● Patient is a female with known menopausal  status at the time of initiation of 
adjuvant ET or male adult ≥18 years -old at the time of informed consent  
● Patient with histologically confirmed unilateral primary invasive 
adenocarcinoma of the breast  
● Patient has breast cancer that is positive for e strogen -receptor and/or 
progesterone -receptor (determined on the most recently analyzed tissue sample 
and tested by a local laboratory based on the ASCO -CAP Guidelines ( Hammond et 
al 2010 )) 
● Patient has  HER2 -negative breast cancer by [CONTACT_14978]  
● Patient has available archival tumor tissue from the surgical specimen  
● Patient after surgical resection where tumor was removed completely, with the 
final surgical specimen microscopic margins fr ee from tumor, and:  
● Patients who received adjuvant chemotherapy and have tumor 
characteristics as defined in the AJCC 8th edition Prognostic Stage Group III  
Note: Categorization into AJCC 8th edition Prognostic Stage Group III requires 
determination of the T - and N -categories, grade of the tumor and ER and PR 
status. Axillary lymph node dissection (ALND) is a preferred method for axillary 
lymph node staging, however sentinel lymph node (SLN) dissection can be 
used to determine the N -category as follows:  
● no metastasis in SLN - patient is considered as having N -
category N0,  
● at least one tumor metastasis larger than 2.0 mm in 1 -2 SLNs in 
a patient with no clinically -detectable lymph nodes, T1 -2 tumors, and no 
gross extra -nodal tumor extension - patient i s considered as having N -
category N1 (This category of selected patients with metastatic SLN and 
no ALND will be limited to no more than 20% of the accrual total),  
● ALND is required to determine the N -category and Prognostic 
Stage Group in all other patie nts, 
or 
● Patients who received neoadjuvant chemotherapy and have 1 or 
more ipsilateral axillary lymph nodes with residual tumor metastases 
greater than 2.0 mm in lymph node( -s) and residual tumor greater than 
10.[ADDRESS_432779] tissue surgical specimen  
[COMPANY_001]  Confidential  Page 12 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 ● Patient has completed multi -agent adjuvant or neoadjuvant chemotherapy of ≥ 
4 cycles or ≥ 12 weeks in duration which included taxanes in the regimen  
● Patient has completed adjuvant radiotherapy (if indicated) according to the 
institutional guidelines prior  to screening  
● Patient has no contraindication for the adjuvant ET and is planned to be treated 
by [CONTACT_348405] 5 years or more  
● Patient may already have initiated ET at the time of randomization, but 
randomization must take place within [ADDRESS_432780] adjuvant ET. 
Ovarian suppression for fertility preservation is not considered adjuvant ET  
● Patient has an Eastern Cooperative Oncology Group (ECOG) Performance 
Status  0 or 1  
● Patient has adequate bone marrow and organ function per pre -defined criteria 
as assessed by [CONTACT_6626]  
● Patient has, sodium, potassium, phosphorus, magnesium and total calcium 
laboratory values within normal limits  
● QTcF interval (using Fr idericia’s correction) < [ADDRESS_432781] and all specific details on Inclusion 
Criteria.  
Key Exclusion criteria  ● Patient has received any CDK4/6 inhibitor  
● Patient has received prior treatment with tamoxifen, raloxifene or aromatase 
inhibitors for reduction in risk (chemoprevention) of breast cancer and/or treatment 
for osteoporosis within last 2 years prior to screening  
● Patient has received prior treatment with anthracyclines at cumulative doses of 
450 mg/m² or more for doxorubicin or 900 mg/m² or more for epi[INVESTIGATOR_14962]  
● Patient with distant metastases of breast cancer beyond regional lymph nodes  
● Patient has not recovered fro m clinical and laboratory acute toxicities of 
chemotherapy, radiotherapy and surgery (i.e., patient has adverse events 
attributed to prior anti -neoplastic therapy NCI CTCAE version 4.03 grade ≥1 at day 
of enrollment, excluding alopecia and amenorrhea)  
● Clinically significant, uncontrolled heart disease and/or cardiac repolarization 
abnormality ( per defined criteria)  
● Clinically significant cardiac arrhythmias  
● Uncontrolled hypertension with systolic Blood Pressure >160 mmHg  
● Patient is currently receiving any of the following prohibited substances and 
cannot be discontinued 7 days prior to Cycle 1 Day 1: concomitant medications, 
herbal supplements, and/or fruits and their juices that are known as strong 
inhibitors or inducers of CYP3A4/5; medications that have a narrow therapeutic 
window and are predominantly metabolized through CYP3A4/5; systemic 
corticosteroids ≤ [ADDRESS_432782] not fully 
recovered from side effects of such treatment; concomi tant medications with a 
known risk to prolong the QT interval and/or known to cause Torsades de Pointes 
that cannot be discontinued or replaced by [CONTACT_64077].  
● Patient has any concurrent severe and/or uncontrolled medical condition that 
would, in the investigators judgment cause unacceptable safety risks, 
contraindicate patient participation in the clinical study or compromise compliance 
with the protocol, or limit life expectancy to ≤5 years  
● Pregnant or breast -feeding (lactating) women or women who plan to become 
pregnant or breast -feed during the study  
● Women of child -bearing potential defined as all women physiologically capable 
of becoming pregnant, unless they are using highly effective methods of 
contraception during the study trea tment and for [ADDRESS_432783] and all specific details on Exclusion 
Criteria.  
Investigational and 
reference therapy  During Treat ment phase ribociclib  will be given orally once a day on days 1 -21 of 
each 28 day cycle. Days 22 -28 of each cycle will be a “rest” period from ribociclib. 
[COMPANY_001]  Confidential  Page 13 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Endocrine therapy (ET) will be given orally once a day on a continuous daily 
schedule (e.g., days 1 -28 of each 28 -day cycle). GnRH agonist (examples include 
but not limited to goserelin, triptorelin or leuprolide) will be given every 4 weeks for 
pre-menopausal women only. There will be no “rest” period in the ET schedule.  
The study drugs will be administe red as a flat -fixed dose, and not by [CONTACT_14987]. All oral study treatment drugs must be administered together 
at approximately the same time each day and can be given with or without food. 
Evening or night doses are strongly not recom mended.  
Recurrence assessments  Recurrence  (including local, regional, or distant,  or contralateral invasive breast 
cancer, or second primary non -breast invasive cancer ) will be assessed by 
[CONTACT_348406], as clinically 
indicated, or at any time when recurrence is suspected .  
Suspi[INVESTIGATOR_348382], 
bone scan, ultrasound, PET, plain X -ray films, or mammography, and maybe 
confirmed by [CONTACT_348407] l (or cytological, when applicable) examination .  
Safety assessments  ● Physical examinations  
● Height, weight, and vital signs  
● 12 lead ECGs  
● Laboratory assessments including hematology, biochemistry, coagulation, 
pregnancy tests (for women of childbear ing potential) and urinalysis  
● All adverse events (AEs) will be reported until end of the [ADDRESS_432784] cancer, adjuvant, 
ribociclib, endocrine the rapy, CDK4/6, Phase II, estrogen receptor -positive, 
progesterone receptor -positive  
[COMPANY_001]  Confidential  Page 14 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Amendment 2 (17-Apr-2018) 
Study CLEE011G2301 was initiated on June 20, 2017 . On 19 January 2018, a planned safety 
review by [CONTACT_348408].  
The study had an early  enrollment  closure on 1 2 February , 2018 ; the decision to close 
enrollment was not based on safety concerns.  As of 1 2 February 2018, 54 female patients 
were randomized at sites in the [LOCATION_002] (U .S.) only.  All randomized patients were  
unblinded ; patients randomized to the placebo arm  permanently discontinue d the study  after 
the safety follow -up assessment  and patients randomized to the ribociclib arm were  offered 
the opportunity to continue investigational treatment with ribociclib + ET for a maximum of 
26 cycles. The decision to continue ribociclib was left to investigator and patient discretion.  
Amendment Rationale  
1. The study was closed to enrollment  early . The main purpose of this amendment is  to 
evaluate the preliminary  safety and tolerability of the ribociclib + ET in patients that were 
randomized to ribociclib + ET prior to the early closure of enrollment , and  to allow 
patients randomized to ribociclib + ET to continue treatment for a maximum of 26 cycles 
if desired, b ased upon investigator and patient decision. Patients were randomized in the 
U.S. only.  
2. In another [COMPANY_001] study CLEE011E2301 (MONALEESA -7) an imbalance in the QT 
prolongation was observed in the subgroup of patients receiving tamoxifen versus non-
steroidal aromatase inhibitors in combination with ribociclib while the overall safety 
profile was comparable. Specifically, a greater than expected QT prolongation was 
observed in the tamoxifen with placebo group  (Tripathy et al 2017 ). [COMPANY_001] is continuing 
to analyze the MONALEESA -7 study results to better understand the efficacy and safety 
data of combination of tamoxifen and ribociclib. However, due to availability of 
alternative therapi[INVESTIGATOR_348383] -1 protocol (i.e. letrozole, anastrozole, or 
exemestane), tamoxifen is not permitted to be used in combination with ribociclib in this 
study.  
As of 12 February 2018 , there were no patients  in the study on treatment by [CONTACT_348409] .  
3. Changes were introduced to the ribociclib dose adjustment and management 
recommendations in Table 6 -5 to mitigate the risk of subsequent QTcF prolongation in 
patients who experienced QTcF prolongation > [ADDRESS_432785] of care.  
5. The lists of prohibited medications and medications to be used with caution during study 
drug trea tment were updated, along with other updates.  
Changes to the protocol  
Section 1.2, Section [IP_ADDRESS], Section 2.4, Section 2.5, Section 4.1.2, Section 6.1.1, Table 6.1, 
Section 6.3.4, Section 6.5, Table 6.7 and Table 6.8 are revised to remove tamoxifen . 
[COMPANY_001]  Confidential  Page 15 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Section 1.2.2  Update with a new clinical data from [CLEE011E2301] (MONALEESA -7) 
study  related to tamoxifen . 
Section 2.1, Section 2.2, Section 5.1, Section 6.4.1, Section 6.4.[ADDRESS_432786] been unblinded . 
Section 2.2, Section 2.4, Section 2.5, Section 4.1, Section 6.1.1 and section 6.4.2 are revised 
to remove the men a s no man has been enrolled at the time of the enrolment termination.  
Section 4.1 , Section 4.1.2, Section 4.1.3, Section 4.3 , Section 6.1.1, Section 6.1. 2, Table 7. 1, 
Section 7.1 .2 and  Section 7. 1.5 are revised as the unblinded patients will continue on 
ribociclib + ET arm till end of treatment (26 cycles maximum) and the patient under placebo 
discontinued the study. The follow up phase is removed.  
Table  3-1, Section 4, Section 6, Section 7  and Section 9 are revised as placebo is removed.  
Figure  4-1 has been removed as only patients randomized to riboc ilib are in the treatment 
phase and the follow up phase is not applicable anymore.  
Section 4.1.2, Section 6.4.1 and Table 7 -1 are revised to remove the use of IRT system at 
randomization as no longe r applicable.  
Section 4.1.2, Section 6.1.1, Table 7 -1, Section 7.1.3, Section 7.2.1, Table 7 -2, Table 7 -3, 
Appendix 2 and Appendix 3 are revised as the r ecurrence is assessed periodically  by 
[CONTACT_348410] . 
Section [IP_ADDRESS]  is revised as the follow up  phase is no longer applicable.  
Section 4.[ADDRESS_432787] an option to be enrolled in a separate protocol,  if applicable, by [CONTACT_348411]. In addition, the maximal duration of the study has been updated.  
Section 6.1 and Table 6.8 are revised as ET will be supplied locally.  
Table 6.5 is revised for updating Ribociclib/placebo dose adjus tment and management 
recommendation for QTcF prolongation . 
Section 7.1.1, Table 7 -1, Section 7.2.2 and Section [IP_ADDRESS] are revised to remove the 
performance status (ECOG).  
Table 7 -4 is removed as the performance status (ECOG) is no longer applicable in the  study.  
Section 7.2.1 is revised to specify that the recurrence will be assessed by [CONTACT_348412], as clinically indicated, or at any time 
when recurrence is suspected . 
Section 7.2.2, Section 7.2.5 and  Table 7. 1 are revised to remove  Patient Reported Outcomes 
that are no longer applicable in the study . 
Table 7.9  is removed as PRO assessments are no longer applicable in the study.  
Section [IP_ADDRESS] and  Table 7.5 are revised as all the laboratory assessments will be performed 
locally, and not centrally anymore . 
[COMPANY_001]  Confidential  Page 16 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Section [IP_ADDRESS] and  Table 7.7 are revised as all the ECGs assessments will be performed 
locally, and not centrally anymore . 
Section [IP_ADDRESS], Table 7 -1, Section  [IP_ADDRESS] .[ADDRESS_432788] 
discontinued the study treatment and the safety follow -up. 
Appendix 4 , Table 14 -4 is revised to remove the strong CYP2D6 inhibitors or inducers (for 
patients receiving tamoxifen)  and to update the Medications List with a known risk for QT 
prolongation . 
Appendix 4, Table 14 -5 is revised to remove the strong CYP2 C9 substrates with NTI (for 
patients receiving tamoxifen)  and to update the Medications List with possible  risk for QT 
prolongation . 
Appendix 5 is removed as  PRO assessmen ts are no longer applicable in the study . 
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities , as required . 
The changes described in this amended protoco l require IRB/IEC approval prior to 
implementation.  
The changes herein  affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.  
[COMPANY_001]  Confidential  Page 17 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Amendment 1 ( 21-Jun-2017)  
Study CLEE011G2301 was initiated on June 20, 2017 . 
Amendment Rationale  
The main purpose of this amendment is to address the recommendation from the Health 
Authorities to exclude patients with rare hereditary problems of galactose intolerance, the 
Lapp lactase deficiency, glucose -galactose malabsorption or soy allergy due to excipi[INVESTIGATOR_348384]. In addition, minor clarifications to inclusion criterion, study assessments and 
procedures were provided as described below.  
Chan ges to the protocol  
 Section 4.1.2  and 6.1.1: Clarification was added  that when investigators  change ET in the 
event of intolerable toxicity, patient’s request, or any other medically important event that 
required change of ET , there is no need to notify No vartis medical monitor.  
 Section 5.2 and Protocol Summary: Inclusion criteria 7 was updated to clarify that patients 
are eligible after surgical resection where tumor was removed completely with the final 
surgical specimen microscopic tumor margins free fro m tumor.  
 Section 5.3: Exclusion criteria 4 was updated to clarify that patients with a known 
hypersensitivity to any of the excipi[INVESTIGATOR_348385] (e.g. rare hereditary problems of 
galactose intolerance, the Lapp lactase deficiency, glucose -galactose malabs orption  or soy 
allergy) will not be eligible for the study.  
 Section 6.1 and 6.5.2 (Table 6 -8): It was clarified that ET wil l be sourced locally or will 
be supplied by [CONTACT_348413].  
 Table 7.1: To address inconsistency between Table 7 -1 and Table 7 -7, clarification was 
provided to Table 7 -1 that the ECG assessment is performed at Cy cle 7 Day 1 in all 
patients.  
 Section [IP_ADDRESS]: Clarification was added that the ECG  assessment should be performed at 
least 3 business days prior to the scheduled randomization date to ensure ECG evaluation 
is received from central laboratory in time for eligibility assessment. Also, patient initials 
will not be collected on ECG tracings . 
 Section [IP_ADDRESS].1 and Protocol Summary : Clarification was provided to the 
Pharmacogenetics Assessments section that genome -wide association studies (GWAS) 
will include exploration of inherited ge netic factors such as CYP3A4 (e.g. CYP3A4 
polymorphism ) tha t may affect the response (both adverse [e.g. neutropenia] and 
therapeutic effects) to treatment . 
 Section 7.2.4: Clarification was added  to address the inconsistency between Table [ADDRESS_432789] treatment follow up phase.  
[COMPANY_001]  Confidential  Page 18 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  Section [IP_ADDRESS].2: Clarification was added that any additional exploratory analysis on 
biomarkers (e.g. CYP3A4 polymorphism) will be detailed in SAP . 
 Section 14.4: List of prohibited medications during study tre atment was updated as 
follows; v enlafaxine was moved from  medications with a known risk for QT  prolongation 
category to medications that carry a possible risk for QT prolongation . Loperamide wa s 
added to the medications that carry a possible risk for QT prolongation . 
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
The changes herein  affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.  
[COMPANY_001]  Confidential  Page 19 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 [ADDRESS_432790] cancer (BC) is the most frequently diagnosed cancer worldwide. Approximately 1.7 
million new cases of BC and 522,000 deaths attributed to BC were estimated to occur in 2012 
worldwide ( Torre et al 2012 ). BC incidence varies between individuals of different ethnicities 
and in different geographic locations around the world with rates ranging  from 27 per 100,000 
in Middle Africa and Eastern Asia to 92 in Northern America ( GLOBOCAN 2012 ). In the 
[LOCATION_002], BC was projected to be the most common cancer diagnosed in 2016 with an 
estimated i ncidence of 249,260 new cases and 40,890 deaths attributed to BC ( Siegel et al 
2016 ). Estimated incidence of BC in European countries in 2012 was 458,337 ( Ferlay et al 
2013 ). BC in men is not common with a reported frequency of approximately 1% of all BC, 
but the incidence of this disease in m en is continuously rising ( Eggeman et al 2013 ). 
The vast ma jority of newly diagnosed BC cases are early breast cancers (EBC) localized to 
the breast tissue and regional lymphatics and which are potentially curable with locoregional 
treatment modalities , such as surgery and radiation therapy. Based on Surveillance,  
Epi[INVESTIGATOR_623], and End Results Program (SEER) data collected between years 1975 and 2012, 
93% of cases of BC diagnosed were EBC, with 61% limited to the breast tissue and 32% 
localized within the breast tissue and regional lymph nodes ( Howlander et al 2015 ). 
1.1.2  Treatment of EBC  
Besides primary surgery, management of EBC usually includes additional anti -neoplastic 
treatment modalities such as radiation therapy and adjuvant or neoadjuvant systemic therapy. 
Although many patients with EBC may be rendered disease -free with surgical resection and 
radiotherapy, distant recurrence  due to not clinically evident at presenta tion ( “micro -
metastatic ”) disease is common and is the primary cause of death in patients with EBC 
(Anampa et al 2015 ). According to the EBC Trialists’ Collaborative Group (EBCTCG) meta -
analysis of almos t 150,000 women in 200 randomized clinical trials, approximately 36% and 
20% of patients with EBC without any adjuvant systemic therapy will experience recurrence  
and death due to BC, respectively, during 5 years of follow up ( EBCTCG 2005 ). Moreover, 
recurrence s and BC -related deaths in patients with hormone receptor (HR) -positive EBC 
continue to occur after 5 years from surgery, with only 45% of patients reported to be 
recurrence -free at 15 years of foll ow-up. 
Adjuvant systemic treatments that comprise cytotoxic, biological and endocrine therapi[INVESTIGATOR_348386] s, decrease BC -specific 
mortality and improve overall survival ( EBCTCG 2005 ). The need and selection of systemic 
adjuvant therapi[INVESTIGATOR_348387], 
pathological and genomic predictive and prognostic factors of tumor and patient such as 
tumor stage, histopathological grade, tumor HR content, human epi[INVESTIGATOR_13392] -2 (HER2 ) amplification status, multi -gene testing recurrence scores, menopausal 
[COMPANY_001]  Confidential  Page 20 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 status, patient’s comorbidities, age, and others. Using these factors, EBC can be classified as 
having low, intermediate /moderate  or high risk for recurrence  after surgery ( Anampa et al 
2015 ). While there is no consensus on definition of these risk groups, generally, patients with 
smaller tumors, no metastasis in regional lymph nodes, low tumor grade, HR -positive and 
HER2 -negative status, and low recurrence genomic score have also low risk of recurrence  (i.e., 
5-10% recurrence s at 5 -years). These patients are usually considered for adj uvant endocrine 
treatment, without chemotherapy, due to a lower clinical benefit of latter versus the former. 
On the other hand, patients with metastases in multiple regional lymph nodes, high tumor 
grade, HER2 -positive status or high recurrence genomic sc ore have a higher risk of recurrence  
if not treated . These patients are usually considered for adjuvant chemotherapy ( HER2  
targeting agents are offered to patients with HER2 -positive BC), and if the tumor expressed 
HR, endocrine adjuvant therapy is considered too (usually delivered after the completion of 
chemotherapy). Complexity and importance of risk definition  in EBC  reflected in the recent 
8th edition of the American Joint Committee on Cancer ( AJCC) Cancer Staging System  for 
patients with bre ast cancer  (Hortobagyi et al 2017 ). This Staging System  included 
pathological features ( i.e. histopathological grade) and biomarkers status (hormone receptors 
and H ER2) in addition to anatomic spread of the tumor (i.e. specific T -, N- and M -categories ) 
to define prognostic stage groups that have similar treatment approaches  and prognosis 
(survival) of patients treated with current standard multimodality treatment (Amin 2016 ). 
Chemotherapy to reduce recurrence risk can be administered preoperatively too. While no 
significant difference in long -term outcomes between adjuvant and neoadjuvant 
chemotherapy was found, neo adjuvant chemotherapy increases rates of breast conservation by 
[CONTACT_348414] ( Mauri et al 2005 ). For example, extent of residual disease after 
neoadjuvant chemotherapy correlates with disease -specific survival (DSS) when patients with 
less than complete pathological response tend to have a higher disease -specific mortality and 
patients with residual disease in lym ph nodes had poorer outcomes than patients with residual 
disease in the breast tissue only ( Jeruss et al 2008 ). 
It is estimated that 75% of BC express receptors for steroid hormones (estrogen and/or 
progesterone) ( Hammond et al 2010 ), and therefore may benefit from endocrine therapy with 
tamoxifen or aromatase inhibitors (AIs) (letrozole, anastrozole or exemestane). Endocrine 
therapy  (ET) , independent of chemotherapy , reduces the risk of recurrence  and BC deaths in 
HR-positive EBC  (EBCTCG 2005 ). Current clinical guidelines for adjuvant ET in the HR -
positive EBC recommend for premenopausal women use of  (1) 5 -10 years of tamoxifen with 
or without ovarian suppression (ovarian suppression is recommended for women with high 
risk for recurrence  after adjuvant chemotherapy), or (2) 5 years of AI with ovarian 
suppression. Clinical guidelines and expert opi[INVESTIGATOR_1649] s recommend for postmenopausal women, 
either (1) initial AI for 5 years (or up to 10 years, based on recently reported results of 
MA.17R, a randomized clinical trial of extending adjuvant letrozole for 5 years after 
completing  initial 5 years ( Goss et al 2016 )), or (2) initial tamoxifen for 2 -3 years followed by 
[CONTACT_348415] 5 years, or up to 5 years of treatment with AI, or (3) tamoxifen for ~5 
years followed by 5 years of AI, or (4) tamoxife n up to 10 years ( Gradishar et al 2016 ; Senkus 
et al 2016 ). Limited data on EBC in men suggest that tamoxifen without gonadotropin -
releasing hormone ( GnRH ) agonist should be the ET of choice for HR -positive, HER2 -
negative EBC ( Fentiman et al 2006 ; Eggeman et al 2013 ; Sousa et al 2013 ). 
[COMPANY_001]  Confidential  Page 21 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 In spi[INVESTIGATOR_348388] a multimodality management of EBC, 
recurrence s are still common, especially in patients with a dverse clinical, pathological and 
geno mic features. Approximately 25%-30% of patients with HR -positive, HER2 -negative 
EBC with multiple (≥4) metastatic regional lymph nodes will recur  within 5 years with the 
therapy that includes AIs ( EBCTCG  2015 ). In addition, worse clinical outcomes are observed 
in patients with EBC that ha d residual disease in lymph nodes after neoadjuvant 
chemotherapy ( Mittendorf et al 2011 ). Therefore, new therapeutic strategies are required to 
improve clinical outcomes in patients with high risk EBC . 
1.1.3  Role of the CDK4/[ADDRESS_432791] in BC  
While ET is effective in treatment of HR -positive advanced BC, approximately 30 -50% of 
patients may not resp ond to it due to  a primary resistance. Moreover, many advanced BC 
patients with initial response to ET will acquire secondary resistance to these agents ( Bachelot 
et al 2012 ; Nichols 2015 ). Co -targeting the estrogen receptor (ER) with other key intracellular 
proliferation and cell survival signaling pathways, such as mechanisms responsible for cell 
cycle regulation and progression may enhance first -line endocrine responsiveness of BC 
tumors by [CONTACT_348416].  
Cell cycle progression is regulated by [CONTACT_4721] -dependent serine -threonine protein kinases 
(CDKs). Extracellular growth and adhesion signals increase the level and function of cyclin D 
proteins within the cell. In turn, the cyclin D proteins associate with and activate CDK4 and 
CDK6 ( Musgrove et al 2011 ). CDK4 and CDK6 phosph orylation leads to inactivation of the 
retinoblastoma protein (Rb) and thus releases E2F, which in turn leads to the transcription 
initiation of proteins involved in cell cycle propagation and proliferation. The luminal A and 
B subtypes of BC (85% of which  are ER -positive and HER2 -negative) have high rates of 
cyclin D/CDK activation; in the luminal A and B subtypes, cyclin D1 (CCND1) 
amplifications were observed in 29% and 58%, and CDK4 amplifications were observed in 14% 
and 25% , respectively ( Holm et al 2012 ; The Cancer Genome Atlas Network 2012 ). Luminal 
A subtype tumors also have loss of CDKN2A, which encodes p16INK4A, a CDK inhibitor 
(Beroukhim et al 2010 ). The luminal subtypes also maintain expression of Rb, which is 
essential for benefit from treatment with a CDK4/6 inhibitor ( Thangavel et al 2 011). 
Dysregulation of cell cycle checkpoints is common in BC, and in all cancers in general, and 
may have clinical and therapeutic significance . For example, p atients with HR -positive BC 
exhibiting a gene expression signature [CONTACT_286805] a shorter recurrence -free survival 
following adjuvant tamoxifen ( Bosco et al 2007 ). A tumor gene expression signature [CONTACT_4007] E2F 
activation is also associated with higher residual tumor cell proliferation following 
neoadjuvant AI therapy. Therefore, activation of the CDK4/[ADDRESS_432792] promotes 
endocrine resistance, and treatment with a CDK4/[ADDRESS_432793] 
thus abrogating endocrine -resistant cell proliferation.  
Selective inhibitors of CDK4/6, such as palbociclib and ribociclib , inhibit proliferation and 
induce apoptosis in preclinical models of endocrine -resistant breast cancer ( Miller et al 2011 ; 
Thangavel et al 2011 ; [Ribociclib Investigator ’s Brochure ]). Both palbociclib and ribociclib 
demonstrated synergy with endocrine treatments in preclinical studi es and efficacy in clinical 
[COMPANY_001]  Confidential  Page 22 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 studies in patients with HR -positive, HER 2-negative advanced BC  (Finn et al 2009 ; 
[Ribociclib Investigator ’s Brochure ]). Addition of palbociclib to letrozole improved median 
progression -free survival (PFS) from 10.2 months to 20.2 months (hazard ratio 0.49, 95% CI: 
0.32-0.75, p=0.0004) in a randomized, open -label, multicenter phase II study ( Finn et al 2015 ) 
and from 14.5 mo nths to 24.8 months (hazard ratio 0.58, 95% CI: 0.46 -0.72, p<0.0001) in a 
phase III study in systemic non -adjuvant treatment -naive postmenopausal women with ER -
positive, HER2 -negative advanced BC ( Finn e t al 2016 ). In addition, in a phase III study in 
521 pre- and postmenopausal patients with advanced HR -positive, HER2 -negative BC that 
had relapsed  or progressed during prior ET, addition of palbociclib to fulvestrant  (with 
ovarian suppression in premenopa usal women in both arms)  improved median PFS from 3.8 
months to 9.2 months (hazard ratio 0.42; 95% CI: 0.32 -0.56; p<0.001) ( Turner et al 2015 ). In 
the subgroup analysis of this study, palbociclib -containing regimen has similar efficacy in 
pre-/perimenopausal  vs post-menopausal women and PFS results were not significantly 
associated with plasma estrogen (E2) levels ( Loibl et al 2016 ), supporting use of palbocicli b 
in pre -/perimenopausal women.  
Efficacy and safety of the combination of ribociclib and letrozole as first line treatment was 
evaluated in 668 postmenopausal women with HR -positive, HER2 -negative advanced BC in a 
phase III stud y ([CLEE011A2301 ]). Ribociclib significantly improved PFS (hazard ratio 0.56, 
95% CI: 0.43 -0.72, p = 0.00000329) ( Hortobagyi et al 2016 ). Refer to the most recent 
[Ribociclib Investigator ’s Brochure ] for more details . 
Considering demonstrated efficacy of CDK4/6 inhibitors in the HR -positive, HER2 -negative 
advanced BC, co -targeting the CDK4/[ADDRESS_432794] with CDK4/6 inhibitors may be a 
viable strategy to enhance endocrine responsiveness and prevent or d elay the development of 
acquired resistance , and it should be explored in the adjuvant setting too.  
1.2 Introduction to investigational treatments and other study 
treatments  
This study includes treatments with ribociclib (LEE011), tamoxifen, anastrozole, letro zole, 
exemestane, and GnRH agonist ( such as goserelin, triptorelin or leuprolide) . 
1.2.[ADDRESS_432795] CDK4/cyc lin-D1 and CDK6/cyclin -D3 enzyme 
complexes.  
[IP_ADDRESS]  Non-clinical data 
Ribociclib inhibits the phosphorylation of Rb at CDK4/6 -binding sites with an average IC50 
of 60 nM in Jeko -1 MCL cells that overexpress cyclin D1. Regardless of the various genetic 
aberrations that may be present in the cancer cells, the anti -tumor activity of ribociclib 
requires the presence of functional pRb.  
Cardiac safety studies  in vivo  demonstrated QT prolongation with the potential to induce 
premature ventricular contractions (PVCs) at higher exposure levels.  The effects of ribociclib 
on the bone marrow (hypocellularity), lymphoid system (lymphoid depletion), intestinal 
[COMPANY_001]  Confidential  Page 23 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 mucosa (atrophy), the kidney (concurrent degeneration and regeneration of tubular epi[INVESTIGATOR_15129]), skin (atrophy), bo ne (decreased bone formation) and testes (atrophy) are considered to 
be related to the pharmacological inhibition of cell replication in these tissues due to CDK4/6 
inhibition. The hepatobiliary system  (proliferative changes, cholestasis, sand -like gallbla dder 
calculi and inspi[INVESTIGATOR_14919]) was identified as an additional target organs of toxicity that are 
not likely related to the primary pharmacology of ribociclib . Generally, all these effects of 
ribociclib demonstrated either reversibility or a clear trend towards reversibility.  Ribociclib 
did not show an indication for a genotoxic potential. Reproductive studies in animals  have 
demons trated that ribociclib is embryotoxic , fetotoxic and teratogenic.  
In vitro , ribociclib was a reversible inhibitor of human cytochrome P450 (CYP) enzymes 
CYP1A2, CYP2E1 and CYP3A4 and a time -dependent inhibitor of CYP3A4. Under 
therapeutic conditions , inhibition of CYP3A4 is likely to occur, while inhibition of CYP1A2 
or CYP2E1 is not expected . The in vitro inhibitory potency o f ribociclib for the transporters 
breast cancer resistance protein  (BCRP ), organic cation transporter 2 ( OCT2 ), multidrug and 
toxin extrusion protein -1 (MATE1 ), and bile salt export pump  (BSEP ) may translate into 
clinically relevant i nhibition at therapeut ic doses.  
Elimination of ribociclib is dominated by [CONTACT_348417]3A4 with a 
minor contribution by [CONTACT_14997] -containing monooxygenase 3 (FMO3). Although ribociclib is a 
substrate of the P -glycoprotein (P -gp) efflux transporter, this proce ss is likely not clinically 
relevant due to the high pass ive permeability of ribociclib.  
Refer to the most recent [Ribociclib Investigator ’s Brochure ] for additional details . 
[IP_ADDRESS]  Clinical experience  
Ribociclib is being investigated in patients  with BC and other  solid tumors  in multiple clinical 
trials  at different phases  of development . Refer to the most recent [Ribociclib Investigator ’s 
Brochure ] for details on clinical studies with ribociclib . 
[IP_ADDRESS].1  Clinical safety of ribociclib  
Clinical safety of ribociclib with endocrine agents such as letrozole, tamoxifen, exemestane 
and fulvestrant has been being evaluated in several phase I and III combination trials. The 
recommended dose of ribociclib in combination with t hese agents was declared as 600 mg  
once daily on days 1 -21 of a 28 day cycle  schedule.  
Safety profile of ribociclib in combination with letrozole was investigated in a randomized 
clinical trial of ribociclib and letrozole versus placebo and letrozole  ([CLEE011A2301 ]) in 
[ADDRESS_432796] common treatment -emergent AEs reported in the ribociclib arm in this study occurring 
in >30% of patients were neutropenia (74.3%), nausea (51.5%), infections (50.3%), fatigue 
(36.5%), diarrhea (35.0 %), alopecia (33.2%) and leukopenia (32.9%). The most common 
grade 3 or 4 AEs reported in ≥5 % of patients in the ribociclib arm were neutropenia (59.3%), 
leukopenia (21.6%), hypertension (9.9%), increased alanine aminotransferase (9.3%), 
lymphopenia (6.9% ) and increased aspartate aminotransferase (5.7%). Febrile neutropenia 
occurred in 1.5% of the patients in the ribociclib arm. Four patients (1.2%) met the 
biochemical and clinical criteria for Hy’s Law with 3 reported as treatment -related and all 4 
[COMPANY_001]  Confidential  Page 24 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 return ing to normal values after treatment discontinuation. Eleven patients (3.3%) presented 
on treatment QTcF prolongation >480 msec. Serious AEs were reported in 21.3% of patients 
in the ribociclib arm with 7.5% of serious AEs  deemed by [CONTACT_348418]-related. 
Neutropenia, QT interval prolongation and hepatobiliary toxicity are considered to be  
important identified risks for ribociclib which appear to be manageable and reversible with 
adequate  monitoring, interruption and/or reduction of ribociclib dosing.  
For a comprehensive review of safety profile of ribociclib  in combination with endocrine 
agents refer to the most recent [Ribociclib  Investigator ’s Brochure ]. 
[IP_ADDRESS].2  Clinical efficacy with ribociclib  
In a phase III randomized clinical trial of ribociclib and letrozole versus placebo and letrozole 
([CLEE011A2301 ]) in 668 treatment -naive postmenopausal women with HR-positive, HER2 -
negative, advanced BC , ribociclib improved PFS (hazard ratio 0.56, 95% CI: 0.43 -0.72, 
p=0.00000329). The investigator -reported overall response rate was 40.7% (95% CI: 35.4% -
46.0%) in the ribociclib arm and 27.5% (95% CI: 22.8% -32.3%) in the placebo arm 
(p=0.000155) in the full analysis set; and 52.7% (95% CI: 46.6%, 58.9%) and 37.1%  (95% CI: 
31.1%, 43.2%) (p=0.[ZIP_CODE]) in patients with measurable disease at baseline ( Hortobagyi et al 
2016 ). 
Refer to the most recent [Ribociclib Investigator ’s Brochure ] for additional details  on efficacy 
profile of ribociclib . 
[IP_ADDRESS].3  Clinical pharmacokinetics of ribociclib  
Following oral dosing  of the capsule formulation at 600 mg, ribociclib is rapi[INVESTIGATOR_348389] T max of 2.4 0 h (range: 0.683 to 7.82 h) . Steady -state plasma C max range s from  
606-6170 ng/mL (geometric mean : 1820 ng/mL or 4.1 µM)  and AUC 0-24h range s from 6770 -
[ZIP_CODE] ng*h/mL (geometric mean : [ZIP_CODE] ng*h/mL). The effective T 1/2 of ribociclib is 32.0 h 
(range: 8.06 to 97.9 h). Inter-patient variability in C max and AUC is 62% and 66%, 
respectively, as assessed by [CONTACT_348419] (CV%). LEQ803, an active 
metabolite of ribociclib, ha s similar PK characteristics as parent drug. At the 600 mg dose 
level, LEQ803 account s for approximately 8% of parent exposure  after single and multiple 
doses. Neither ribociclib nor LEQ803 accumulate substantially following repeated daily 
administration.  
Ribociclib undergoes extensive hepatic metabolism via CYP3A in humans based on in vitro 
and in vivo studies. Ribociclib is mainly eliminated via hepatic clearance, with renal clearance 
playing a lesser role in humans. The majority of the administered dose was excreted in feces  
(69.1%), with a minor amount excreted in urine (22.6%). Ribociclib accounted for 
approximately 23% of the total radioactivity in plasma  ([CLEE011A2102 ]). The most 
prominent metabolites in plasma are CCI284 (N -hydroxylation), LEQ803 (N -demethylation), 
and M1 ( secondary glucuronide ), each representing <10% of total radioactivity . The clinical 
activity (pharmacological and safety) of ribociclib is primarily due to parent drug, with a 
negligible contribution from circulating metabolites.  
Concomitant use of rib ociclib with strong CYP3A4 inhibitors or strong CYP3A4 inducers 
should be avoided as ribociclib exposure may be markedly affected. Co -administration of a 
[COMPANY_001]  Confidential  Page 25 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 strong CYP3A4 inhibitor (ritonavir) increased ribociclib AUC by 3.2 -fold following a single 
oral dose of 400 mg ribociclib ( [CLEE011A2101 ]). Co -administration of a strong CYP3A4 
inducer (rifampi[INVESTIGATOR_2513]) decreased ribociclib AUC inf by 89% following a single oral dose of 600 
mg ribociclib ( [CLEE011A2101 ]). 
Ribociclib is a moderate to strong inhibitor of CYP3A4, but did not have a substantial effect 
on CYP1A2 substrates in humans ( [CLEE011A2106 ]). Co -administration of midazolam 
(CYP3A4 substrate) with multiple doses of ribociclib (400 mg) increased midazolam 
exposure by 3.8 -fold. Co -administration of caffeine (CYP 1A2 substrate) with multiple doses 
of ribociclib (400 mg) increased caffeine exposure by 20% (1.2 -fold). Concurrent use of 
sensitive CYP3A4 substrates with a narrow therapeutic index should be avoided. Concurrent 
use of CYP1A2 substrates is not expected to  lead to clinically important DDIs.  
Food does not affect the PK of ribociclib administered as a capsule or tablet formulation; 
therefore ribociclib capsules or tablets can be taken without regard to meals 
([CLEE011A2111 ], [CLEE011A2103 ]). 
Refer to the  most recent [Ribociclib Investigator ’s Brochure ] for additional details.  
1.2.[ADDRESS_432797] cancer. AIs can be use d either as an upfront therapy or after 2 -3 
or 5 years o f prior tamoxifen  (see Section 1.1.2 ). The long -term efficacy of both approaches 
of AIs administration is similar ( EBCTCG 2015 ). Clinical treatment guidelines suggest that 
there is no compelling evidence showing meaningful clinical efficacy or toxicity differences 
between the letrozole, anastrozole and exemestane ( Gradishar et al 2016 ), therefore similar 
precautions and monitoring activities should apply irrespective of type of AI administered. 
GnRH agonists are used to achieve ovarian suppression in premenopausal wom en. Tamoxifen 
(without GnRH agonist) is the adjuvant therapy of choice for men with HR -positive EBC (see 
Section 1.1.2 ).  
In another [COMPANY_001] study CLEE011E2301 (MONALEESA -7) an imbalance in the QT 
prolongation  was observed in the subgroup of patients receiving tamoxifen versus non -
steroidal aromatase inhibitors in combination with ribociclib while the overall safety profile 
was comparable. Specifically, a greater than expected QT prolongation was observed in th e 
tamoxifen with placebo group ( Tripathy et al 2017 ). [COMPANY_001] is continuing to analyze the 
MONALEESA -7 study results to better understand the efficacy and safety data of 
combination of tamoxifen and rib ociclib. However, due to availability of alternative therapi[INVESTIGATOR_348390] -1 protocol (i.e. letrozole, anastrozole, or exemestane), tamoxifen 
is not permitted to be used in combination with ribociclib in this study.  
[IP_ADDRESS]  Overview of letrozole  
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system. Letrozole 
acts by [CONTACT_348420] ( mainly from adrenal  glands , 
the primary source of estrogens in postmenopausal women) to estrogens. Letr ozole induces a 
75% to 95% decrease of estrogen levels after two weeks of treatment with daily doses of 0.1 
[COMPANY_001]  Confidential  Page 26 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 to 5 mg, with no significant clinical and laboratory toxicities or changes in levels of other 
hormones of the endocrine system ( Lipton et al 1995 ; Trunet et al 1996 ). 
Letrozole is administered orally once daily at a dose of 2.[ADDRESS_432798] of letrozole clearance.  
Letrozole  (2.5 mg daily)  and ribociclib (600 mg, qd, 3 weeks on/1 week off) did not affect 
metabolism of each other  in a phase Ib/II dose escalation/expansion study ( [CLEE011 X2107 ]). 
Additionally, in a phase III study  ([CLEE011A2301 ]), ribociclib had no effect on letrozole 
PK based on a comparison of letrozole PK data between treatment groups . 
The most frequently reported AEs for letrozole in the adjuvant and extended adjuvant clinical 
trials were hot flashes, arthralg ia/arthritis and myalgia. In general, the observed adverse 
reactions were  mild to moderate in intensity . Adjuvant use of letrozole is associated with a 
decrease in bone mass density which may lead to osteoporosis and associated bone fractures. 
Consideration should be given to monitoring bone mass density.  
Due to its mechanisms of action, letrozole, as well as other AIs , should not be used for above -
mentioned indications in women with  an intact ovarian fu nction or in non -castrated men.  
Refer to t he most recent regional prescribing information  for more information on letrozole.  
[IP_ADDRESS]  Overview of anastrozole  
Anastrozole , like letrozole,  is a selective non -steroidal AI. It significantly lowers serum 
estradiol concentrations with no detectable effect on for mation of adrenal corticosteroids or 
aldosterone.  
Anastrozole is administered orally once daily at a dose of 1 mg , taken with or without food . 
Anastrozole is metabolized by N -dealkylation, hydroxylation and glucuronidation. Hepatic 
metabolism accounts for approximately 85% of anastrozole elimination. Renal elimination 
accounts for approximately 10% of total clearance. The major circulating metabolite of 
anastrozole lacks pharmacologic activity. Anastrozole metabolism occurs mainly via CYP3A4 
and UGT1A4 base d on in vitro data ( Edevana et al 2013 ). Therefore, anastrozole metabolism 
may potentially  be affected by [CONTACT_3252] -administration with ribociclib. However, anastrozole has 
been studied up to doses of 10 mg/day  (10-times daily dose)  and all doses evaluated were well 
tolerated with no serious acute toxicities  attributed to anastrozole ( Plourde et al 1995 ). 
Refer to the most recent regional prescribing information  for more information on anastrozole.  
[IP_ADDRESS]  Overview of exemestane  
Exemestane is a steroidal irreversible AI that is initially recognized by [CONTACT_348421] a false substrate and is then transformed through an NADPH -dependent mechanism to an 
intermediate that binds irreversibly to the enzyme, causing inactivation. Exemestane 
significantly lowers circulating estrogen concentrations (estradiol, estrone and estrone sulfate) , 
but has no detectable effect on adrenal biosynthesis of corticosteroids or  aldosterone  (Goetz et 
al 2015 ). 
[COMPANY_001]  Confidential  Page 27 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 The recommended daily dose of exemestane is [ADDRESS_432799]-pass metabolism, but is increased when taken with food. Exemestane is metabolized by 
[CONTACT_097]3A4 and aldoketoreductases. It does not inhibit any of the major CYP isoenzymes, 
including CYP1A2, 2C9, 2D6, 2E1 and 3A4 ( Buzdar 2003 ). 
Although no formal drug -drug interaction studies have been conducted, significant effects on 
exemestane clearance by [CONTACT_348422]. The most frequently 
reported adverse effects for exeme stane are gastrointestinal disturbances, hot flushes, 
arthralgia, myalgia, sweating, fatigue, and dizziness. Reductions in bone mineral density can 
occur with long -term use of exemestane. Exemestane is generally well tolerated, and AEs are 
usually mild to moderate. Androgenic effects were reported in a limited number of patients 
(Buzdar 2003 ). 
Refer to the most recent regional  prescribing information  for more information on exemestane . 
[IP_ADDRESS]  Overview of GnRH ag onists  
GnRH agonists are synthetic analogues of gonadotropin -releasing hormone that by [CONTACT_286761][INVESTIGATOR_286735].  
GnRH agonists differ from the naturally -occurring GnRH by [CONTACT_348423] n(-s) in the 
decapeptide structure (usually by [CONTACT_286763] 6, but also in positions 9 
and 10)  to decrease degradation  of the molecule . Examples for GnRH agonists for use in this 
study  include but not limited  to goserelin, triptorelin or leuprolide. One-mont h depot 
formulation of GnRH agonists must be used to suppress ovarian function in premenopausal 
women  in this study  as the 3 -month depot formulations do not reliably suppress estrogen 
levels in all patients ( Gradishar et al 2016 ). 
The most common AEs occurring of women treated with goserelin (one of the GnRH agonists) 
included hot flushes, headache, sweating, acne, emotional lability, depression, decreased 
libido, vaginitis, breast atrophy, seborrhea and peripheral edema . 
Refer to the most recent regiona l prescribing information  and/or clinical guidelines  for more 
information on GnRH agonists . 
2 Rationale  
2.1 Study rationale and purpose  
While adjuvant ET for HR -positive EBC is effective in reducing risk of recurrence  and 
improving survival , recurrence s are still common, especially in patients with unfavorable 
clinical , pathological  and/or molecular  features. These recurrence s, mostly in the form of 
distan t metastases, are usually incurable and will eventually translate into BC death s. 
Since addition of CDK4/6 inhibitor ribociclib to ET has proven  clinical efficacy with tolerable 
toxicity  profile in HR -positive, HER2 -negative advanced BC, its use in the adj uvant setting 
may decrease risk of recurrence s in patients with HR -positive, HER2 -negative EBC with high 
risk for presence of micro -metastatic disease after surgical resection of the primary tumor by 
[CONTACT_76644] 28 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 enhancing primary endocrine responsiveness and preventin g, or delaying the development of 
acquired resistance for ET . 
Therefore, the purpose of this study was to evaluate  the effect of  addition of ribociclib to 
standard adjuvant ET on invasive disease -free survival (iDFS) in patients with HR -positive, 
HER2 -negative EBC with adverse clinical and/or pathological features that predispose 
patients for an increased risk of recurrence . 
The study enrollment was early closed on 12 February 2018 . All randomized patients were 
unblinded; patients randomized to placebo  permanently discontinued study treatment and 
patients randomized to ribociclib were offered the option to continue treatment with ribociclib 
+ ET (excluding tamoxifen). The purpose of this amended  protocol is to evaluate the 
preliminary  safety data on the  combination of ribociclib + ET in HR+, HER2 -negative high -
risk EBC patients who enrolled in  this study prior to the early closure of the enrollment and to 
allow  patients randomized to ribociclib + ET  to continue treatment with ribociclib + ET for a 
maximum of [ADDRESS_432800] adjuvant ET in patients with HR -positive, 
HER2 -negative high risk EBC.  
The study has been closed to enrollment. All randomized patients were unblinded; patients 
randomized to placebo permanently discontinued study treatment and patients randomized to 
ribociclib were offered the option to con tinue treatment with ribociclib + ET (excluding 
tamoxifen).  
The study include d pre- and postmenopausal women with HR -positive, HER2 -negative EBC  
that have high risk o f recurrence  (“high risk EBC”)  after standard multimodality therapy . 
Pre-menopausal women were included in addition to post -menopausal women since major 
differences in efficacy and safety of ribociclib are not expected in these populations of 
patients. In planned subgroup analysis of the palbociclib phase III clinical trial of fulvestrant 
with ribociclib vs fulvestrant with placebo in  patients with advanced HR -positive, HER2 -
negative BC  (ovarian suppression was achieved with goserelin in pre -/perimenopausal 
patients in both arms), no differences in efficacy and safety profile were observed in pr e-
/perimenopausal vs postmenopausal patients ( Turner et al 2015 ; Loibl et al 2016 ). In addition, 
palbociclib did not alter ovarian function suppressio n and PFS in pre -/perimenopausal patients 
was not significantly associated with plasma estrogen (E2) levels ( Loibl et al 2016 ). To 
mitigate potential differences between pre - and postmenopausal women  in this study, 
randomization by a meno pausal status will be employed.  
Patients with high risk for recurrence  included in this study are the following two groups (the 
rationale for including each group is provided below) : 
1. Patients who received adjuvant chemotherapy and have tumor characteristics as defined in 
the AJCC 8th edition Prognostic Stage Group III (see Table 14 -1 in Appendi x 1) 
Note:  Categorization  into AJCC 8th edition Prognostic Stage Group III requires 
determination of the T - and N -categories, grade of  the tumor , and ER and PR status. 
Axillary lymph node dissection (ALND) is a preferred method for axillary lymph node 
[COMPANY_001]  Confidential  Page 29 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 staging , however  sentinel lymph node (SLN) dissection can be used to de termine  the N -
category as follows:  
 no metastasis in SLN  - patient is considered having N -category N0 , 
 at least one tumor metastasis larger than 2.0 mm in 1 -2 SLNs in a patient with no 
clinically -detectable lymph nodes , T1 -2 tumors, and no gross extra -nodal tumor 
extension  - patient is considered having N -category N1 , 
 ALND is required to determine the N -category and  Prognostic Stage Group in all 
other patients . 
2. Patients who received neoad juvant chemotherapy and have 1 or more ipsilateral axillary 
lymph nodes with residual tumor metastases greater than 2.0 mm in lymph node( -s) and 
residual tumor greater than 10.[ADDRESS_432801] that Prognostic Stage Groups that 
incorporate anatomical staging (i.e. T -, N- and M -categories) with histopathological grade and 
biomarker status  (i.e. HR and HER2  status) predict prognosis after standard multimodality 
treatment (including adjuvant chemotherapy and ET) better than classification based solely on 
the anatomic extent of the disease  (Hortobagyi et al 2017 ). 
Recently, SLN  dissection without subsequent ALND in case of metastatic SLN  became 
acceptable  practice in selected patients following the results of the ACOSOG Z0011 clinical 
trial where  patients with metastatic SLN were randomized to either ALND  or no additional 
surgery . The trial  demonstrated comparable 5 -y disease -free survival (83.9% vs 82.2%  in 
SLN dissection only and SLN dissection followed by [CONTACT_348424] , respectively) and OS (92.5% vs 
91.8%, respectively) between the two arms  and le ss surgical co -morbidity with SLN 
dissection only  (Giuliano et al 2011 ). This approach has been recommended by [CONTACT_348425]  (Coates et al 2015 ; Senkus et al 2015 ; Gradishar et al 
2016 ; Lyman et al 2016 ). Since in  the ALND arm  of Z0011 ~85% of patients  had N1 disease  
(Giuliano et al 2011 ), patients who conform with the trial eligibility criteria ( T1-2, <3 
metastatic SLNs, no clinically -evident nodal disease before the surgery, no gross extranodal 
tumor extension, no neoadjuvant systemic therapy, and were treated with lumpectomy with 
adjuvant radiotherapy) can be considered as having N -category N1 for the purpose of 
assignme nt these patients  to the AJCC 8th edition Prognostic Stage Group.  
The rationale for including patients treated with neoadjuvant chemotherapy is that 
neoadjuvant chemotherapy is one of the recommended treatment options for patients with 
EBC (see Section 1.1.2 ). To be eligible  for this trial , patients treated by [CONTACT_348426], since these 
characteristics were shown to be associated and/or pred ictive for high risk for recurrence ( von 
Minckwitz et al 2012 ) and worse DSS (Jeruss et al 2008 ). 
Randomization will be stratified by a menopausal status, stage group  and geographical region 
(see Section 4.1 ). Menopausal status was selected as a stratification factor  since  it may reflect 
different treatment choice s and prognosis. Premenop ausal women will be combined with men 
in the same stratum since both men and premenopausal women may have higher recurrence 
rate compared to postmenopausal women  and number of men is expected to be small to make 
[COMPANY_001]  Confidential  Page 30 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 it as a separate stratum.  During the randomization,  patients with metastatic SLN( -s) and no 
ALND will be limited to no more than 20% of the accrual total.  
The primary efficacy of the investigational intervention will be evaluated by [CONTACT_348427] ( Hudis et al 2007 ). The definition of iDFS in the 
STEEP System is broad, clinically -relevant and includes the most co mmonly accepted DFS 
events used in published trials for EBC . 
2.3 Rationale for dose and regimen selection  
The dose ( oral administration of 600 mg daily ) and regimen ( Days 1 -21 of a 28 day cycle) of 
ribociclib was s elected for this study since this  dose and reg imen were shown to be tolerable 
and efficacious when combined with ET in clinical trials in patients with HR -positive, HER2 -
negative advanced BC (see Section 1.1.2 ). In this trial, ET that is combined with ribociclib or 
placebo will be administered according to local clinical guidelines and regional prescribing 
information . 
Due to  a protracted pattern of recurrences of HR-positive, HER2 -negative EBC , with the 
majority of  events observed  starti ng from  a year after the surgery ( EBCTCG 2015 ), a short 
duration (i.e. ≤12 months) of ribociclib  treatment might not be sufficient  for a  meaningful 
impact on recurrence rate of EBC. In order to provide s ufficient ribociclib  exposure  while 
balancing potential toxicity of prolonged treatment with  the medication , ribociclib (or placebo ; 
both in combination with the ET ) will be administered for 26 cycles (approximately 24 
months ) in this study . 
2.[ADDRESS_432802] 
reversible and manageable toxicities (see Section 1.2 ). 
Ribociclib will be combined with the standard ET that has been approved for adjuvant 
treatment  of EBC and will include either letrozole, anastrozole, or exemestane, with GnRH 
agonist (in premenopausal w omen  only)  administered according to the local clinical 
guidelines and regional prescribing information  (see Section 1.1.2 ). In premenopausal women  
with high risk EBC , ET will include ovarian suppression by [CONTACT_348428] . GnRH agonist 
will be administered every 4 weeks  subcutaneously . 
2.5 Rationale for choice of comparators drugs  
Since, all patients randomized to placebo discontinued study participation at the end of safety 
follow up, this section is longer applic able.  
2.6 Risks and benefits  
Based on preclinical and clinical data, treatment of ribociclib in combination  with ET is 
expected to be tolera ble and toxicities of the treatment are expected to be manageable and 
reversible upon dose reduction, treatment interru ption or discontinuation . 
[COMPANY_001]  Confidential  Page 31 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Patients in this study will be carefully monitored for key toxicities that have been observed 
with ribociclib (see Section 1.2.1 ) or endocrine treatments (see Section 1.2.2 ). Risk will be 
further minimized by [CONTACT_140983]/exclusion selection criteria (see Section 5 ), 
avoidance of prohibited medication (see Section 6.3.3 ), close safety monitoring (see Section 8 ) 
and dose adjustment guidelines (see Section 6.2 ). 
Since the study was closed to enrollment and all patients were unblinded, the [COMPANY_001] study 
team will monitor safety in conjunction with the [COMPANY_001] Safety Management Team.  
3 Objectives and endpoints  
Objectives and related endpoints are described in Table 3 -1 below.  
Table 3-1 Objectives and related endpoints  
Objective  Endpoint  Analysis  
Primary   Refer to Section 10  
To evaluate the preliminary safety and 
tolerability of the ribociclib + ET in patients 
that were randomized to ribociclib + ET 
prior to the early closure of enrollment.  Tolerability and Safety of the 
treatment regimen based on 
frequency and severity of AEs, 
laboratory and ECG abnormalities   
The study has an early enrollment  closure . All randomized patients were unblinded . Health related quality of life, 
hospi[INVESTIGATOR_113493], blood and tissue samples for biomarkers will no longer be collected and analyzed.  
4 Study design  
4.1 Description of study design  
This was a randomized, phase III, double -blind, placebo -controlled , multi -center,  international 
study  to evaluate efficacy and safety of ribociclib with ET as an adjuvant treatment in patients 
with HR-positive, HER2 -negative, high risk EBC . 
The study has been closed to enrollment. All randomized patients were unblinded; pa tients 
randomized to placebo permanently discontinued study treatment and patients randomized to 
ribociclib were offered the option to continue treatment with ribociclib + ET (excluding 
tamoxifen). Patients randomized to placebo have to complete 30-day safety follow up after the 
last dose of placebo.  
Following the protocol amendment 02, this stu dy is  an open label, multi -center phase II 
conducted in the US only.  
The study will include  
 Screening phase  (28 days ); this phase has been completed for all patients as of 1 2 
February 2018  
 Treatment phase  composed of 26 cycles  of ribociclib treatment  (approximately 24 months) 
in combination with ET  (where treatment with ET may start up to 12 weeks  before the 
date of rando mization ) and [ADDRESS_432803] dose of ribociclib ; 
[COMPANY_001]  Confidential  Page 32 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  During treatment phase , patients will be treated with combination of ribociclib + ET for a 
maximum of [ADDRESS_432804]-treatment follow -up phase assessments are not 
performed. For each patient randomized to placebo + ET, study participation will end 
following the safety follow -up after the end of treatment (EOT) within [ADDRESS_432805] 
dose of placebo. For each patient randomiz ed to ribociclib + ET, study participation will end 
following the safety follow -up after the EOT after the last dose of ribociclib. Patients  in 
follow -up phase will end study participation following the protocol amendment 02.  
4.1.[ADDRESS_432806] 
adjuva nt endocrine therapy  (ET) prescribed by [CONTACT_3433] e investigator (tamoxifen , letrozole, 
anastrozole, or exemestane , with GnRH agonist for premenopausal women; only tamoxifen 
will be allowed to be used in men ). ET may start ≤ [ADDRESS_432807]:  
 Obtain  signed  informed consent from the patient prior to any study procedures  
 Assess the inclusion and exclusion criteria as detailed in Section 5  
 Perform all screening pro cedures as detailed in Table 7 -1 
Results of all screening/baseline evaluations must be reviewed by [CONTACT_15009]/her 
designee prior to enrollment of each patient into the study to assure that a ll inclusion and 
exclusion criteria have been satisfied.  
4.1.[ADDRESS_432808] administered every 4 wee ks 
(examples include but not limited to  goserelin , triptorelin or leuprolide) . Patients receiving 
GnRH agonist should be regularly monitored per local institutional  clinical guidelines to 
confirm a postmenopausal value of gonadotropin and sex hormones  according to local 
laboratory ranges . 
Study treatment will continue until completion of a maximum of 26 cycles of ribociclib  
treatment  (approximately 24 months) , first recurrence  (any of the following or combination of 
local, regional or distant recurrence s, or contralateral invasive breast cancer, or second 
primary non-breast invasive cancer), intolerable toxicity, withdrawal of consent by [CONTACT_102], 
patient is lost to follow up, death, or discontinuation from the study treatment due to any other  
reason  or the sponsor terminates the study , whichever is earlier. 
[COMPANY_001]  Confidential  Page 33 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 During treatment with ribociclib , investigators will not be allowed to change ET unless 
intolerable toxicity, patient’s request, or any other medically -important event that require s 
change of ET  (Investigator should clearly  document in the eCRF the reason for changing of 
ET during the treatment with ribociclib . After end of treatment with ribociclib  no further 
information will be collected after the safety follow -up assessment [ADDRESS_432809] dose of ribociclib  and will 
include routine safety monitoring except in case of death, loss to follow up or withdrawal of 
consent.  
4.1.3  Follow up  phase  
[IP_ADDRESS]  Post treatment follow -up 
Starting with the protocol amendment 02, follow -up phase assessments are not performed.  
[IP_ADDRESS]  Survival follow up 
Starting with the protocol amendment 02, survival follow up will not be performed.  
The end of the study for a given patient is defined when the patient permanently discontinues 
study specified treatments  and all the end of trial procedures for that individual patient are 
completed.  For a patient randomized to placebo + ET, study participation will end following 
the safety follow -up after the end of treatment (EOT) after the last dose of placebo. For 
patient randomized to ribociclib + ET, study participation will end following the safety 
follow-up within [ADDRESS_432810] dose of ribociclib.   
[IP_ADDRESS]  Timing of interim analyses and design adaptations  
Following  early  enrolment closure and unblinding of the patients’ randomization arm, the 
interim analyses are no longer planned. The final data ana lysis is planned to be performed 
after all patients discontinue the ribociclib treatment and complete the safety follow -up 
assessment [ADDRESS_432811] patient’s last dose of ribociclib.  
4.[ADDRESS_432812] discontinued ribociclib treatment  and 
completed the safety follow -up period  (until [ADDRESS_432813] patient on treatment has been enrolled in another 
[COMPANY_001]  Confidential  Page 34 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 [COMPANY_001] -sponsored  protocol  that will allow treatment continuation for patients who benefit ed 
from the study treatment  with ribociclib . 
The study is expected to continue for maximum approximately 25 months (24 months + 30 
day follow -up) and will end once the last patient randomized to ribociclib has completed 
safety their follow -up safety assessment within [ADDRESS_432814] dose of ribociclib.  
4.3 Early study termination  
The study can be terminated at any time for any reason by [CONTACT_5343]. Should this be necessary,  
the patient should be seen as soon as possible and the same assessments should be performed 
as described in Section 7  for a discontinued or withdrawn patient. The investigator may be 
informed of additio nal procedures to be followed in order to ensure that adequate 
consideration is given to the protection of the patient’s interests. The investigator will be 
responsible for informing IRBs and/or ECs of the early termination of the trial.  
5 Population  
5.1 Patient  population  
The study include s men and pre- and postmenopausal women with HR -positive , HER2 -
negative high risk EBC  after adequate surgical resection, radiotherapy  (if indicated) , adjuvant 
or neo -adjuvant chemotherapy , and who are deemed to be eligible for adjuvant ET for at least 
[ADDRESS_432815] ensure that only patients who meet all the follo wing 
inclusion and none of the exclusion criteria are offered treatment in the study.   
The study has been closed to enrollment. All randomized patients were unblinded; patients 
randomized to placebo permanently discontinued study treatment and patients ran domized to 
ribociclib were offered the option to continue treatment with ribociclib + ET (excluding 
tamoxifen).  
5.[ADDRESS_432816] to meet all of the following criteria:  
1. Written informed consent must be obtained prior to any screening procedures  
2. Patient is  a female with known menopausal status at the time of initiation of (neo-) 
adjuv ant therapy /GnRH agonist  or male adult  ≥18 years -old at the time of informed 
consent  
Note: Postmenopausal status is defined when : 
 patient under went bilateral oophorectomy, or  
 age ≥ 60 years, or  
[COMPANY_001]  Confidential  Page 35 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  age < 60 years and amenorrhea for 12 or more months (in the absence of 
chemotherapy, tamoxifen, or ovarian suppression) and FSH and plasma estradiol are 
in the postmenopausal range s per local normal range , or 
 For women with therapy -induced amenorrhea, seri al measurements of FSH and/or 
estradiol per local clinical guidelines are required for  determination of 
postmenopausal status  
All non postmenopausal women are considered premenopausal  
3. Patient with histologically confirmed unilateral primary invasive adenoc arcinoma of the 
breast  
4. Patient has breast cancer that is positive for estrogen -receptor and/or progesterone -
receptor ( determined on the most recently analyzed tissue sample  and tested by a local 
laboratory based on  the ASCO -CAP Guidelines ( Hammond et al 2010 )) 
5. Patient has HER2 -negative breast cancer defined as a negative in situ  hybridization test or 
an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ  hybridization (FISH, CISH, or  
SISH) test is required (based on the most recently analyzed tissue sample and all tested by 
a local laboratory)  
6. Patient has available archival tumor tissue from the surgical specimen  
7. Patient after surgical resection where tumor was removed completely, wit h the final  
surgical specimen microscopic margins free from tumor, and:  
 Patients who received adjuvant chemotherapy and have tumor characteristics as 
defined in the AJCC 8th edition Prognostic Stage Group III (see Table 14 -2 in 
Appendix 1 ) 
Note:  Categorization  into AJCC 8th edition Prognostic Stage Group III requires 
determination of the T - and N -categories, histo pathological grade of the tumor and 
ER and PR status. ALND is a preferred method for axillary lymph node staging, 
however  SLN dissection can be used to determine the N -category as follows:  
 no metastasis in SLN - patient is considered as having N -category N 0, 
 at least one tumor metastasis larger than 2.0 mm in 1 -2 SLNs in a patient with no 
clinically -detectable lymph nodes, T1 -2 tumors, and no gross extra -nodal tumor 
extension - patient is considered as having N -category N1 . (This category of 
patients with metastatic SLN and no ALND will be limited to no more than 20% 
of the total accrual) , 
 ALND is required to determine the N -category and Prognostic Stage Group in all 
other patients , 
or 
 Patients who received neoadjuvant chemot herapy and have 1 or more ipsilateral 
axillary lymph nodes with residual tumor metastases greater than 2.0 mm in lymph 
node (-s) and residual tumor greater than 10.[ADDRESS_432817] tissue surgical specimen  
8. Patient has completed multi -agent adjuvant or neoadjuvant chemotherapy of ≥ 4 cycles or 
≥ 12 weeks in duration which included taxanes in the regimen  
9. Patient has completed adjuvant radiotherapy  (if indicated)  according to the institutional 
guidelines prior to screening  
[COMPANY_001]  Confidential  Page 36 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 10. Patient has no contra indication for the adjuvant ET and is planned to be treated by [CONTACT_348405] 
[ADDRESS_432818] adjuvant ET. Ovarian suppression for fertility 
preservation is not considered adjuvant ET 
12. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1  
13. Patient has adequate bone marrow and organ function as defined by [CONTACT_286767] (as assessed by [CONTACT_286768]):  
 Absolute neutrophil count ≥ 1.5 × 109/L 
 Platelets ≥ 100 × 109/L 
 Hemoglobin ≥ 9.0 g/dL  
 Estimated  glomerular filtration rate ( eGFR) ≥ 30 mL/min  by a  Cockcroft -Gault 
formula . 
 Alanine transaminase (ALT) ≤ 1.5 × ULN  
 Aspartate transaminase (AST) ≤ 1.5 × ULN  
 Total serum bilirubin ≤ ULN ; or total bilirubin ≤ 3.0 × ULN with direct bilirubin ≤ 
1.5 × ULN  of the central laboratory  in patients with we ll documented Gilbert’s 
Syndrome  
 International normalized ratio ( INR) ≤ 1.5 (unless the patient is receiving 
anticoagulants and the INR is within the therapeutic range of intended use for that 
anticoagulant within [ADDRESS_432819] dose of study drug) 
 Patient must have the following laboratory values within normal limits or corrected to 
within normal limits with supplements (the central laboratory value should be 
documented within normal limits after the correction) before the first dose of study 
drug: 
 Sodium  
 Potassium  
 Phosphorus  
 Magnesium  
 Total Calcium  
14. Standard 12 -lead ECG values defined as the mean of the triplicate ECGs and assessed by 
[CONTACT_2237]:  
 QTcF interval (using Fridericia’s correction) at screening < 450 mse c 
 Mean r esting hear t rate 50 -90 bpm  (determined from the ECG)  
15. Subjects must be able to communicate with the investigator and comply with the 
requirements of the study procedures  
16. Must be willing to remain at the clinical site as required by [CONTACT_348429] 37 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 17. Premenopausal women mu st have confirmed negative pregnancy test (for β -hCG) during 
the screening period and before starting study treatment unless this patient had a 
hysterectomy  
18. All sexually active male patients are required to use a condom during intercourse while 
taking drug  and for [ADDRESS_432820] not meet any of the following criteria:  
1. Patient has received any CDK4/6 inhibitor  
2. Patient has received prior treatment with tamoxifen, raloxifen e or AIs for reduction in risk 
(“chemoprevention ”) of breast cancer and/or treatment for osteoporosis  within last 2  years 
prior to screening  
3. Patient  has received prior treatment  with anthracyclines at cumulative doses of 450  mg/m² 
or more for doxorubicin or 900 mg/m² or more for epi[INVESTIGATOR_14962]  
4. Patient with a  known hypersensitivity to any of the excipi[INVESTIGATOR_140898] , ET and 
placebo (e.g. rare hereditary problems of galactose intolerance, the Lapp lactase 
deficiency, glucose -galactose malabsorption, and soy allergy)  
5. Patient with distant metastases o f breast  cancer  beyond regional lymph nodes  
6. Patient is concurrently using other anti -neoplastic  therapy  with the exception of adjuvant 
ET (for duration of no more than 12 weeks ) from the date of randomization  
7. Patient has had major surgery , chemotherapy or radiotherapy  within 14 days prior to 
starting treatment with ribociclib or placebo  
8. Patient has not recovered from clinical and laboratory acute toxicities of chemotherapy, 
radiotherapy and surgery ( i.e., patient has AEs attributed to prior anti -neoplastic  therapy 
NCI CTCAE version 4.03 grade ≥1 at day of enrollment, excluding alopecia  and 
amenorrhea ) 
9. Patient has a concurrent malignancy or malignancy within 5 years prior to screening, with 
the exception of adequately treated, basal or squamous cell carcinoma  of the skin or 
curatively resected cervical carcinoma in situ  
10. Patient has a history of HIV infection (testing is not mandatory)  
11. Patient has active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection  (testing is 
not mandatory)  
12. Clinically significa nt, uncontrolled heart disease and/or cardiac repolarization abnormality, 
including any of the following:  
 History of documented myocardial infarction (MI), angina pectoris, symptomatic 
pericarditis, or coronary artery by[CONTACT_9292] (CABG) within 6 months pr ior to study 
entry  
 Documented cardiomyopathy  
 Left Ventricular Ejection Fraction (LVEF) < 50% as determined by [CONTACT_140989] (MUGA) scan or echocardiogram (ECHO)  (testing not mandatory)  
[COMPANY_001]  Confidential  Page 38 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  Long QT syndrome or family history of idiopathic sudden de ath or congenital long 
QT syndrome, or any of the following:  
 Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or 
hypomagnesemia, history of cardiac failure, or history of clinically 
significant/symptomatic bradycardia  
 Concomitant medication(s) with a known risk to prolong the QT interval and/or 
known to cause TdP that cannot be discontinued or replaced by [CONTACT_348430] (e.g. within 5 half -lives or 7 day s prior to starting study drug)  
 Inability  to determine  the QTcF interval  
 Clinically significant cardiac arrhythmias ( e.g., ventricular tachycardia), complete left 
bundle branch block, high -grade AV block (e.g., bifascicular block, Mobitz type II 
and third degree AV block)  
 Uncontrolled hypertension with s ystol ic blood pressure (SBP) >[ADDRESS_432821] dose of study drug: 
 Concomitant medications, herbal supplements, and/or fruits (e.g., grapefruit, 
pume loes, star fruit, Seville oranges) and their juices that are known as strong 
inhibitors or inducers of CYP3A4/5  
 Medications t hat have a narrow therapeutic window and are predominantly 
metabolized through CYP3A4/5  
14. Patient is currently receiving or has recei ved systemic corticosteroids ≤ [ADDRESS_432822] not fully recovered from side effects of such treatment.  
Note:  The following uses of corticosteroids are permitted: single doses, topi[INVESTIGATOR_14911] (e.g., for rash), inhale d sprays (e.g., for obstructive airways diseases), eye 
drops or local injections (e.g., intra -articular)  
15. Patient has impairment of gastrointestinal (GI) function or GI disease that may 
significantly alter the absorption of the study drugs (e.g., uncontroll ed ulcerative diseases, 
uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel 
resection)  
16.  Patient has any other concurrent severe and/or uncontrolled medical condition that would, 
in the investigator ’s judgment cause  unacceptable safety risks, contraindicate patient 
participation in the clinical study or compromise compliance with the protocol (e.g. 
chronic pancreatitis, chronic active hepatitis, liver cirrhosis or any other significant liver 
disease,  active untreated or uncontrolled fungal, bacterial or viral infections,  active 
infection requiring systemic anti -bacterial therapy, etc.) or limit life expectancy to ≤[ADDRESS_432823] -feeding (lactating) women  or women who plan to become pregnant or 
breast -feed during the study.  
19. Women of child -bearing potential defined as all women physiologically capable of 
becoming pregnant, unless they are using highly effective methods of contraception 
[COMPANY_001]  Confidential  Page 39 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 during the study  treatment and for [ADDRESS_432824] ive contraception methods include:  
 Total abstinence (when this is in line with the preferred and usual lifestyle of the 
patient ). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods) and withdrawal are not acceptable metho ds of contraception  
 Female sterilization (have had surgical bilateral oophorectomy with or without 
hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking 
study treatment. In case of oophorectomy alone, only when the reproductive  status of 
the woman has been confirmed by [CONTACT_104]  
 Male partner sterilization (at least 6 months prior to screening). For female patient on 
the study the vasectomized male partner should be the sole partner for that patient . 
 Placement  of an intrauterine device (IUD)  
Note:  Use of oral (estrogen and progesterone), transdermal, injected or implanted 
hormonal methods of contraception as well as hormonal replacement therapy is not 
allowed in this study  
Note:  Women are considered not of  child bearing potential if they have had 12 months of 
natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age 
appropriate, history of vasomotor symptoms) or have had surgical bilateral 
oophorectomy (with or without hysterectomy), t otal hysterectomy, or tubal ligation at 
least six weeks ago. In the case of oophorectomy alone, only when the reproductive 
status of the woman has been confirmed by [CONTACT_348431]: After the end of study treatment and while on standard endocrine treatment, 
women of child -bearing potential and men should use effective contraception 
according to the local prescribing  information  
6 Treatment  
6.1 Study treatment  
For this study, the term “inves tigational or study drug” refers to [COMPANY_001] study drug ribociclib. 
The other drug s to be used in this study are endocrine therapy (ET), which will be 
administered according to the  local clinical guidelines and  regional prescribing information  
depending on  patient’s needs and according to the investigator’s clinical judgement . 
“Study treatment” in this study refers to the combination of the ET with ribociclib . ET alone 
after discontinuation of the ribociclib  is not considered a “study treatment” . 
Ribociclib  will be supplied by [CONTACT_286771] [ADDRESS_432825] be recorded in the eCRF.  
[COMPANY_001]  Confidential  Page 40 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 6.1.1  Dosing regimen  
All eligible patients will receive starting from Cycle 1 Day 1   
 Ribociclib 600 mg tablets once daily on days 1 to 21 of a 28 day cycle + ET  
Ribociclib  will be given orally once a day on days 1  to 21 in each 28  day cycle. Days 22  to 28 
will be a “rest” from ribociclib  (Table 6 -1). Treatment of ribociclib + ET will continue for 26 
cycles (approximately 24 months).  
ET will be administered according to the local clinical guidelines and regional prescribing 
information  (Table 6 -1). Acceptable ET that will be combined with ribociclib in female 
patients  includes  one of the following medications : 
 Letrozole 2.5 mg by  [CONTACT_348432] y, 
 Anastrozole 1 mg by [CONTACT_34048] , 
 Exemestane [ADDRESS_432826] (examp les include, but not 
limited to , goserelin, triptorelin or leuprolide)  administered every [ADDRESS_432827] -menopausal value of gonadotropin and sex hormones  according to local laboratory 
ranges (see Table 7 -3). 
Patients will be allowed to start ET up to 12 weeks  before the day of randomization. During 
treatment with ribociclib, investigators will not be allowed to change ET unless intolerable 
toxicity, patient’s request, or a ny other medically important event that requires change of ET  
(Investigator must clearly document in the eCRF the reason for changing of ET during the 
treatment with ribociclib ). 
Table 6-1 Dose and treatment schedule  
Study treatments  Pharmaceutical form and 
route of administration  Dose  Frequency and/or Regimen  
Ribociclib  Tablets f or oral use  600 mg  Once daily on days 1  to 21 in each 28 day cycle  
Letrozole  Tablets for oral use 2.5 mg  Days 1 to 28 of a 28 day cycle  
Anastrozole  Tablets for oral use  1 mg Days 1 to 28 of a 28 day cycle  
Exemestane  Tablets for oral use  25 mg  Days 1 to 28 of a 28 day cycle  
GnRH agonists  Per local prescribing information  Day 1 of a 28 day cycle  
Ribociclib will be administered as a flat -fixed dose, and not by [CONTACT_348433].  There will be no breaks between dosing cycles. A complete cycle of treatment is defined 
as 28 days. All study treatment drugs should be administered as descr ibed below in Section 
[IP_ADDRESS]  and Section [IP_ADDRESS] .  
The study has been closed to enrollment. All randomized patients were unblinded; patients 
randomiz ed to placebo permanently discontinued study treatment and patients randomized to 
ribociclib were offered the option to continue treatment with ribociclib + ET (excluding 
tamoxifen). Patients randomized to placebo permanently discontinued treatment and 
completed the safety follow -up assessment. Patients randomized to ribociclib are allowed to 
continue treatment with ribociclib + ET for a maximum of 26 cycles (approximately 24 
[COMPANY_001]  Confidential  Page 41 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 months) or until first disease recurrence, intolerable toxicity, withdrawal of con sent, death or 
discontinuation from the study treatment for any other reason, whichever is earlier . 
The investigator or responsible site personnel should instruct the patient to take the study 
drugs as per protocol ( to promote compliance). Drug accountability must be performed on a 
regular basis. Patients will be instructed to return unused study drugs to the site at the end of 
each cycle. The site personnel will ensure that the appropriate dose of each study drug is 
provided at each cycle . 
[IP_ADDRESS]  General dosing  guidelines  
Study treatment s should be taken as follows:  
 Ribociclib is dosed for the first 21 days of the 28 -day cycle . 
 On scheduled visit days, patients must take study treatments in the clinic under the 
supervision of t he Investigator or designee. On all other days patients may take ribociclib 
at home.  
 Patients should be instructed to take ribociclib  and ET  with a large glass of water (~250 
mL or ~8 oz) at the same time each da y. Patients can determine if they prefer mor ning or 
early afternoon dosing, but they should maintain a consistent time. Evening do ses are 
strongly not recommended.  
 Ribociclib can be adm inistered with or without food.  
 Patients should be instructed to swallow the tablets  whole and not to chew, crush or open 
them.  
 If vomiting occurs during the course of treatment, no re -dosing of the patient is allowed 
before the next scheduled dose. The occurrence and frequency of any vomiting during a 
treatment cycle must be noted in the  adverse events section of the eCRF.  Refer to Section 
[IP_ADDRESS]  for use of anti -emetic medications.  
 Any doses that are missed (not taken within 6 hours of the intended time) should be 
skipped and should not be replaced or made up on a subsequent day.  
 Patients must avoid consumption of grapefruit, grapefruit hybrids, pummelos, star -fruit, 
Seville oranges , pomegranates  or products containing the juice of each during the entire 
study treatment and preferably  [ADDRESS_432828] a potential to  increase exposure to ribociclib . 
Note:  Oranges and o range juice are allowed. Herbal or dietary supplements known as 
strong inhibitors or inducer s of CYP3A4 are prohibited . 
 Multivitamins , glucosamine, probiotics, fish oil  are permitted.  
 GnRH agonist must be administered by [CONTACT_348434] 28 days in accordance with the 
regional prescribing information.  
[IP_ADDRESS]  Additional dosing guidelines for ECG panel collection  
On days with ECG panel, the following additional guidelines should be followed:  
 If a pre -dose ECG measurement is to be collected, then the ECG measurement should 
occur before dosing the study treatment . 
[COMPANY_001]  Confidential  Page 42 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 6.1.2  Guidelines for continuation of treatment  
For guidelines for continuation of treatment  with ribociclib , see Section 6.2  “Dosing 
modification ”. 
Patients who permanently discontinue ribociclib for any reason are considered to have 
completed the treatm ent phase and will proceed  to End of Treatment  (EOT) visit.  
After End of  Treatment, patents may contin ue on the same ET regimen or another ET regimen 
as determined by [CONTACT_348435]’s needs and according to the investigator’s 
clinical judgement . Patients who permanently discontinue ET during the treatment phase will 
also discontinue ribociclib and will move to  End of Treatment.    
6.1.3  Study t reatment duration  
The study has been closed to enrollment. All randomized patients were unblinded; patients 
randomized to placebo permanently discontinued study treatment and patients randomized to 
ribociclib were offered the option to continue treatment with ribociclib + ET  (excluding 
tamoxifen).  
Patients will be treated with ribociclib + ET for 26 cycles  (approximately 24 months ) until 
first recurrence , intolerable toxicity, withdrawal of consent by [CONTACT_102], patient is lost to 
follow up, death, discontinuation from the  study treatment due to any other reason or the 
sponsor terminates the study , whichever is earlier.  
6.2 Dose modifications  
6.2.1  Dose modification and dose delay  
For patients who do not tolerate the protocol -specified dosing schedule, dose adjustments  are 
permitted  in order to allow patient s to continue the study treatment  (Table 6 -2). These dose 
changes must be recorded on the Dosage Administration Record CRF.  
Table 6-2 Dose modification guidelines  
 Ribociclib  
Dose  Number of tablets  & strength  
Starting dose  [ADDRESS_432829] dose reduction  400 mg  2 x 200 mg tablets  
Second dose reduction  200 mg  1 x 200 mg tablet  
[IP_ADDRESS]  Ribociclib   
Recommendations for dose interruption , reduction  or discontinuation of ribociclib in the 
management of study drug related adverse reactions are summarized in Table 6 -3, Table 6 -4, 
Table 6 -5 and Table 6 -6. No dose re -escalation is permitted . 
Clinical judgment of the treating physician sho uld guide the management plan of each patient 
based on individual benefit/risk assessment. However, for events requiring a discontinuation 
in Table 6 -3, Table 6 -4, Table 6 -5 and Table 6 -6 or listed in  Section 7.1 , treatment with 
[COMPANY_001]  Confidential  Page 43 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 ribociclib must be discontinued.  If dosing was interrupted for >[ADDRESS_432830] dos e of ribociclib . 
Unscheduled  local laboratory assessments may be performed and recorded in the eCRF if 
required according to the visit evaluation schedule , for documentation of adverse event, for 
treatment decision  and any clinically significant laboratory  values per investigator’s discretion . 
For assessment of patients’ eligibility to the study, only laboratory results from the central 
laboratory will be used , with exception of FSH and plasma estradiol levels to determine 
menopausal status.  
Table 6-3 Ribociclib dose adjustment and management recommendations for 
hematological adverse reactions  
Toxicity/Grade  Dose Adjustment and Management Recommendations  
Thrombocytope nia 
Grade 1(≥75 x 109 /L) No dose adjustment required.  
Grade 2 (≥50 x 109/L – <75 x 109/L) Dose interruption until recovery to grade 1. 
Re-initiate ribociclib at the same dose.  
Grade 3 (≥25 x 109/L - <50 x 109/L) Dose interruption until recovery to grade 1. 
Re-initiate ribociclib at the same dose level.  
If toxicity recurs at grade 3: temporary dose interruption 
until recovery to grade 1 and reduce ribociclib to the next 
lower dose level.  
Grade 4  (<25 x 109/L) Dose interruption until recovery to grade 1. 
Re-initiate ribociclib at the next lower dose level.  
If toxicity recurs at grade 4: discontinue ribociclib   
Absolute neutrophil count (ANC)  
Grade 1 (≥1.5 x 109/L) No dose adjustment required.  
Grade 2 (≥1.0 - <1.5 x 109/L) No dose adjustment required.  
Grade 3 (≥0.5 - <1.0 x 109/L) Dose interruption until recovery to ≥1.0 x 109/L. 
Re-initiate ribociclib at the same dose level.  
If toxicity recurs at grade 3: temporary dose interruption 
until recovery to ≥ 1.0 x  109/L. 
If resolved in ≤7 days, then maintain dose level.  
If resolved in >7 days, then reduce ribociclib dose to the 
next lower dose level.  
Grade 4 (<0.5 x 109/L) Dose interruption until recovery to ≥ 1.0 x 109/L. 
Re-initiate ribociclib at the next lower dose level.  
Febrile neutropenia  
Grade 3  
ANC <1.0 x 109/L with a single temperature of 
>38.3 ºC (101 ºF) or a sustained temperature of 
≥38 ºC (100.4 ºF) for more than one hour  Dose interruption until improvement of ANC ≥ 1.0 x 109/L 
and no fever. Restart at the next lower dose level.  
If febrile neutropenia recurs, discontinue ribociclib.  
Grade 4  
Life-threatening consequences;  
urgent intervention indicated  Discontinue ribociclib . 
[COMPANY_001]  Confidential  Page 44 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Toxicity/Grade  Dose Adjustment and Management Recommendations  
Anemia  
(Hemoglobin)  
Grade 1 (≥10.0 – LLN g/dL)  No dose adjustment required.  
Grade 2 (≥8.0 – <10.0 g/dL)  No dose adjustment required.  
Grade 3 (<8.0 g/dL)  Dose interruption until recovery to grade  2. 
Re-initiate ribociclib at the same dose.  
Grade 4  
Life-threatening consequences;  
urgent intervention indicated  Discontinue ribociclib.  
Table 6-4 Ribociclib  dose adjustment and management recommendation for 
hepatic toxicities  
HEPATOTOXICITY (BILIRUBIN, SGPT/ALT, SGOT/AST)  
TOTAL BILIRUBIN without  ALT/AST increase above baseline value  
Grade 1 (> ULN – 1.[ADDRESS_432831])  
(confirmed 48 -72h later)  Maintain dose level with LFTs monitored bi -weekly  
Grade 2 (> 1.5 – 3.[ADDRESS_432832])  Dose interruption of ribociclib  
If resolved to ≤ grade 1 in ≤ 21 days, then maintain dose 
level  
If resolved to ≤ grade 1 in > 21 -28 days or toxicity recurs, 
then reduce 1 dose level  
Repeat liver enzyme and bilirubin tests twice weekly fo r 2 
weeks after dose resumption  
If toxicity recurs  after two dose reductions,  or recovery to 
≤ grade 1 i s > 28 days,  discontinue ribociclib  
Grade 3 (> 3.0 – 10.[ADDRESS_432833])  Dose interruption of ribociclib , until resolved to ≤ grade 1, 
then lower 1 dose level of ribociclib   
Repeat liver enzyme and bilirubin tests twice weekly fo r 2 
weeks after dose resumption  
If resolved to ≤ grade 1 in > 2 8 days or toxicity recurs, 
discontinue ribociclib  
Grade 4 (> 10.[ADDRESS_432834])  Discontinue ribociclib  
Confounding factors and/or alternative causes for increase of total bili rubin should be excluded before dose 
interruption/reduction. They include but are not limited to: evidence of liver metastases, evidence of obstruction, 
such as elevated ALP and GGT typi[INVESTIGATOR_348391] s disease, hyperbilirubinemia due to t he indirect 
component only (i.e. direct bilirubin component ≤ [ADDRESS_432835]) due to hemolysis or Gilbert Syndrome, pharmacologic 
treatment, viral hepatitis, alcoholic or autoimmune hepatitis, other hepatotoxic drugs.  
For patients with Gilbert Syndrome, these dos e modifications apply to changes in direct bilirubin only.  
Bilirubin will be fractionated if elevated.  
AST or ALT  
AST or ALT without bilirubin elevation > [ADDRESS_432836]  
Same grade as baseline or increase from baseline 
grade 0 to grade 1  
(confirmed 48 – 72 h later)  No dose adjustment required with LFTs monitored per 
protocol if same grade as baseline or bi -weekly in case 
of increase from baseline grade 0 to 1  
Grade 2 (> 3.0 – 5.[ADDRESS_432837])  Dose interruption of ribociclib  
If resolved to ≤ baseline grade in ≤ 21 days, then 
maintain dose level  
If resolved to ≤ baseline grade in > 21 days or toxicity 
recurs, then reduce 1 dose level  
Repeat liver enzyme and bilirubin tests twice weekly fo r 2 
weeks after dose resumption  
If toxicity recurs after two dose reductions or recovery to 
≤ baseline grade  is > 28 days, discontinue ribociclib     
[COMPANY_001]  Confidential  Page 45 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 HEPATOTOXICITY (BILIRUBIN, SGPT/ALT, SGOT/AST)  
Grade 3 (> 5.0 – 20.[ADDRESS_432838])  Dose interruption of ribociclib   until resolved to ≤ baseline 
grade, then lower 1 dose level of ribociclib   
Repeat liver enzyme and bilirubin tests twice weekly for  2 
weeks after dose resumption  
If recovery to ≤ baseline grade is > 28 days, discontinue 
ribociclib   
If toxicity recurs, discontinue ribociclib  
Grade 4 (> 20.[ADDRESS_432839])  Discontinue ribociclib   
AST or ALT and concurrent Bilirubin  
For patients with normal  ALT and AST and total 
bilirubin at baseline:  AST or ALT >3.[ADDRESS_432840] 
combined with  total bilirubin > [ADDRESS_432841] or ALT or total bilirubin 
at baseline:  baseline: [AST or ALT >2 x baseli ne AND 
>3.0x ULN] OR [AST or ALT >8.[ADDRESS_432842]] - whichever 
is lower - combined with  [total bilirubin > 2 x baseline 
AND >2.[ADDRESS_432843]]  Discontinue ribociclib   
Confounding factors and/or alternative causes for increased transaminases should be excluded before dose 
interruption/reduction. They include but are not limited to:  concomitant medications, herbal preparations or dietary 
supplements, infection, hepato -biliary disorder or obstruction, liver metastas es, and alcohol intake.  
Refer to Section [IP_ADDRESS]  for a dditional follow -up on potential drug -induced liver injury (DILI) 
cases.  
[IP_ADDRESS]  Dose adjustments  for QTc F prolongation  
To determine QTcF duration to use in the following table, measurements o f QT interval 
should be conducted on ECG  and corrected (QTcF).  
Table 6-5 Ribociclib  dose adjustment and management recommendation for 
QTcF prolongation  
Grade  Dose Modification  
For All Grades  1. Check the quality of the ECG and the QT value and repeat if needed.  
2. Perform analysis of serum electrolytes ( sodium, potassium , calcium , phosphorus , 
magnesium ). If outside of the normal range, interrupt ribociclib administration, correct 
with supplements or appropriate therapy as soon as possible, and repeat electrolytes 
until documented as normal.  
3. Review concomitant medication usage  for the potential to inhibit CYP3A4 and/or 
to prolong the QT interval.  
4. Check compliance with correct dose and administration of ribociclib.  
1 
QTcF 450-480 ms ec Perform steps 1 -4 as directed in “For All Grades.” No dose adjustment required.  
2 
QTcF 481-500 ms ec Interrupt ribociclib.  Perform steps 1 -4 as directed in “For All Grades.”  
Perform a repeat ECG within one hour of the first QTcF of ≥ 481 ms ec.  
Repeat ECG as clinically indicated until the QTcF returns to < 481 ms ec.  
Restart ribociclib with dose reduced by 1 dose level. Refer  to Table 6 -2 for dosing 
schedule.  
If QTcF ≥  481 ms ec recurs, ribociclib  should be reduced  again by 1 dose level. Refer 
to Table 6 -2 for dosing schedule.  
Repeat ECGs 7 days and 14 days after dose resumption (then as clinically indicated)  
for any patients who had therapy  interrupted due to QTcF ≥ 481 ms ec 
[COMPANY_001]  Confidential  Page 46 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 3 
QTcF ≥ [ADDRESS_432844] 
two separate ECGs  Interrupt ribociclib. Perform steps 1 -4 as directed  in “For All Grades.”  
Perform a repeat ECG within one hour of the first QTcF of ≥ 501 ms ec. 
● If QTcF remains ≥ [ADDRESS_432845] (or qualified specialist) 
and repeat cardiac monitoring as indicated until the QTcF r eturns to < 481 ms ec. 
● If QTcF returns to <  481 ms ec, ribociclib  will be reduced by 1 dose level. Refer to 
Table 6 -2 for dosing schedule.  
● If QTcF remains ≥ 481 msec  after performing steps 1 -4 as direc ted in “For All 
Grades , discontinue ribociclib.  
Repeat ECGs 7 days and 14 days after dose resumption (then as clinically indicated) 
for any patients who had therapy  interrupted due to QTcF ≥ 501 ms ec 
If QTcF  of ≥ 501 ms ec recurs, discontinue ribociclib   
4 
[QT/QTc F ≥ 501 or > 60 ms ec 
change from baseline]  
and 
[Torsades de pointes or 
polymorphic ventricular 
tachycardia, or signs/symptoms 
of serious arrhythmia]  Discontinue ribociclib.  Perform steps 1 -4 as directed  in “For All Grades.”  
Obtain local cardiologist (or qualified specialist) consultation and repeat cardiac 
monitoring as indicated unt il the QTcF returns to <481 ms ec 
[IP_ADDRESS]  Guidance for all other adverse reactions  
Consider performing an analysis of serum potassium, sodium, calcium, phosphorus, an d 
magnesium for all adverse reactions, if indicated. If electrolyte values are outside of the 
normal range, interrupt ribociclib administration, correct electrolytes with supplements or 
appropriate therapy as soon as possible, and repeat electrolyte testin g until documented 
normalization of the electrolytes.  
Patients who experience renal impairment (not due to other contributing factors) of grade 2 or 
higher during the treatment phase  should discontinue treatment and should be f ollowed for 
safety assessment s. 
For all other AEs please follow recommendations in Table 6 -6. 
Table 6-6 Ribociclib dose adjustment and management recommendation for all 
other adverse reactions  
Grade  Dose Adjustment and Management Recommendations  
1 No dose adjustment recommended. Initiate appropriate medical therapy and monitor.  
2 Dose interruption until recovery to grade 1. Initiate appropriate medical therapy and monitor.  
Re-initiate ribociclib at the same dose.  
If the same toxicity recurs at grade 2, interrupt ribociclib until recovery to grade 1. Re -initiate ribociclib 
at the next lower dose level.  
3 Dose interruption until recovery to grade  1. Initiate appropriate medical therapy and monitor.  
Re-initiate ribociclib at the next lower dose level.  
If toxicity recurs at grade 2: temporary dose interruption until recovery to grade [ADDRESS_432846] weekly  for 
4 weeks, and subsequently at 4 -week intervals, until resolution  or stabilization of the event.  
[COMPANY_001]  Confidential  Page 47 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 All patients will be followed for safety  (routine safety monitoring)  for approximately [ADDRESS_432847] dose of ribociclib. Once an AE is detected, investigators are required to 
follow this AE until its resolution or stabilization. Refer to Section 8.1.1  for definitions and 
reporting of A Es. After 30 days, SAE s that are deemed by [CONTACT_348436] (i.e., combination of ribociclib and ET)  or ET alone  will continue to be 
reported, until withdrawal of consent, death, loss to follow up, or the end of study, whichever 
is earlier.  
[IP_ADDRESS]  Follow up on potential drug -induced liver injury (DILI) cases  
Increase in transaminases combined with total bilirubin (TBIL) increase may be indicative of 
drug-induced liver injury (DILI), and should be considered  as clinically -important event.  
The threshold for potential DILI may depend on the patient’s baseline AST/ALT and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:  
 For patients with normal (i.e. ≤ ULN) ALT and AST and TBIL value at baseline: AST or 
ALT > 3.[ADDRESS_432848]  combined with TBIL > 2.[ADDRESS_432849]  
 For patients with elevated (i.e. > ULN) AST or ALT or TBIL value at baseline: [AST or 
ALT > 2 x baseline AND > 3.[ADDRESS_432850]] OR [AST or ALT > 8.[ADDRESS_432851]], whiche ver is 
lower, combined with [TBIL > 2 x baseline AND > 2.[ADDRESS_432852]]  
Medical review  needs to ensure that liver test elevations are not caused by [CONTACT_15014], defined 
as: ALP elevation > 2.[ADDRESS_432853] with R value < 2 in patients without bone metastasis, or 
elevat ion of ALP liver fraction in patients with bone metastasis.  
(Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN 
for both values. It denotes the relative pattern of ALT and/or ALP elevation is due to 
cholestatic or he patocellular liver injury or mixed type injury).  
In the absence of cholestasis, these patients should be immediately discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferably within 48 hours from 
the awareness of the ab normal results. The evaluation should include laboratory  tests, detailed 
history, physical assessment and the  possibility  of liver metastasis or new liver lesions, 
obstructions/compressions, etc.  
Hepatic toxicity monitoring includes the following LFTs: alb umin, ALT, AST, total bilirubin, 
direct and indirect bilirubin, alkaline phosphatase (fractionated if alkaline phosphatase is 
grade 2 or higher), creatine kinase, prothrombin time (PT)/INR and GGT. For patients with 
Gilbert syndrome: total and direct bilir ubin must be monitored, intensified monitoring applies 
to changes in direct bilirubin only.  
Close observation is recommended in case of AST, ALT, and/or bilirubin increase requiring 
dose interruption, which involves:  
 Repeating liver enzyme and serum biliru bin tests two or three times weekly . Frequency 
of re-testing can decrease to once a week or less if abnormalities stabil ize or return to 
normal values.  
 Obtaining a more detail ed history of current symptoms.  
[COMPANY_001]  Confidential  Page 48 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  Obtaining a more detailed history of prior and/or  concurrent diseases, including history of 
any pre -existing liver conditions or risk factors.  
 Obtaining a history of concomitant drug use (including non -prescription medications, 
herbal and dietary supplements), alcohol use, recreational drug use, and spec ial diets.  
 Ruling out liver metastases  
 Ruling out acute viral hepatitis types A, B, C, D, and E; hepatotropic virus infections 
(CMV, EBV or HSV); autoimmune or alcoholic hepatitis; NASH; hypoxic/ischemic 
hepatopathy; and biliary tract disease.  
 Obtaining a history of exposure to environmental chemical agents.  
 Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR, direct 
bilirubin).  
 Considering gastroenterology or hepatology consultations.  
 Assessing cardiovascular dysfunction or imp aired liver oxygenation, including 
hypotension or right heart failure as possible et iologies for liver dysfunction.  
 Considering liver biopsy as clinically indicated to assess pathological change and degree 
of potential liver injury  
All cases of DILI confirmed on repeat testing meeting the laboratory criteria defined above, 
with no other alternative cause for LFT abnormalities identified, should be considered as 
“medically significant”, thus met the definition of SAE ( Section 8.2.1 ), and must be reported 
as SAE using the term “potential drug -induced liver injury”. All events must  be followed up 
with the outcome clearly documented.  Results of tests as well as other clinically important 
information will be recorde d in the eCRF.  
6.[ADDRESS_432854] be told to notify the investigational site about any new medications he/she 
takes after the start of the study treatment . All medications (other than study treatment ) and 
significant non -drug therapi[INVESTIGATOR_014] (including physical therapy, herbal/natural medications and 
blood transfusions) administered during the study must be listed on the Concomitant 
Medications / Relevant Non -Drug  Therapi[INVESTIGATOR_50061].  
If patients take concomitant medications chronically, any change in dose or schedule of 
concomitant medication throughout the study period should be clearly documented.  
[IP_ADDRESS]  Use of bisphosphonates and denosumab  
Bisphosphonates and denosumab are generally allowed  per local/regional prescribing 
information and clinical guidelines . Administration and reason for bisphosphonate/denosumab 
use must be clearly documented in the eCRF. Refer to regional prescribing information and  
[COMPANY_001]  Confidential  Page 49 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 clinical guidelines  for comprehensive safety and efficacy information an d guidance for each 
medication.  
[IP_ADDRESS]  Corticosteroids  
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to lead to 
induction of CYP3A enzymes, thereby [CONTACT_348437] o f reducing ribociclib 
drug exposure to sub -therapeutic levels. Systemic corticosteroid treatment should not be given 
during the study, except for:  
 Topi[INVESTIGATOR_14929] (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye 
drops or local in jections (e.g., intra -articular);  
 A short duration (< 5 days) of systemic corticosteroids ≤ to the anti -inflammatory potency 
of 4 mg dexamethasone (e.g. for chronic obstructive pulmonary disease).  
[IP_ADDRESS]  Hematopoietic growth factors  
Prophylactic use of WBC growth  factors with ribociclib is not recommended.  
[IP_ADDRESS]  Use of antiemetic medications  
Ribociclib has minimal to low emetogenic potential according to a definition of anti -
neoplastic agent emetogenicity ( Grunberg et  al 2010 ). Antiemetic therapy can be used 
according to clinical guidelines for anti -neoplastic medications with low to minimal 
emetogenic potential for treatment and/or prevention of nausea and vomiting as a result of 
study treatment ( NCCN 2016 ; Roila et al 2016 ). 
Potential drug interaction between ribociclib and antiemetic medications should always be 
taken into consideration. Example of prohibited antiemetic medication is intravenously 
administered ondansetron that in combination with ribociclib may precipi[INVESTIGATOR_14933]. Refer to 
Section 6.3.[ADDRESS_432855] of medications that are allowed or prohibited to be 
used with ribociclib.  
6.3.2  Permitted concomitant therapy requiring caution  
Medications to be used with caution during combined ribociclib  and ET in this study (see 
Table 14 -4 in Appendix 2 ) are listed below. These medications should be avoided if possible. 
If they must be given based on the investigator’s judgment, then use wi th caution  and consider 
a ribociclib  interruption if the concomitant medication is only needed for a short time . 
Following medications should be used with caution and with proper clinical and laboratory 
monitoring : 
 Medications that carry a possible risk for  QT prolo ngation and/or Torsades de Pointes 
(TdP) (may precipi[INVESTIGATOR_348392]; see Section [IP_ADDRESS]  for additional 
details) . 
 Moderate inhibitors or inducers of CYP3A4/5 (may increase or decrease ribociclib 
exposure, respectively - see Section [IP_ADDRESS].3  for additional details) . 
 Sensitive substrates of CYP3A4/[ADDRESS_432856] n arrow therapeutic index (ribociclib 
may increase exposure to these medications - see Section [IP_ADDRESS].3  for additional details) . 
[COMPANY_001]  Confidential  Page 50 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  Based on in vitro  data (see Section [IP_ADDRESS]  for additional details), co -administration of 
ribociclib with strong inhibitors of BSEP (see Table 14 -4 in Appendix 2 ) may lead to 
intrahepatic cholestasis, and co -administration of ribociclib with sensitive substrates of 
MATE1, OCT2, and BCRP has a potential to increase exposure to substrates of these 
transporters, although no animal or clinical data are availab le to support these st atements.  
6.3.3  Prohibited concomitant therapy  
The following medications are prohibited during combined ribociclib  and ET treatment in this 
study ( Table 14 -4 in Appendix 2 ): 
 Strong inhibitors or inducers of CYP3A4/5  (may significantly increase or decrease 
ribociclib exposure, respectively)  
 Herbal medications/preparations that are strong inhibitors or inducers of CYP3A4/5. 
These include, but are not limited to : St. John’s wort, Kava, ephedra (ma huang), gingko 
biloba, DHEA, yohimbe, saw palmetto, black cohosh and ginseng. Patients should stop 
using all herbal medications at least [ADDRESS_432857] dose of study treatment.  
 Substrates of CYP3A4/5 with a narro w therapeutic index  (ribociclib may increase 
exposure to these medications resulting in toxicity to these medications)  
 Medications with a known risk for QT prolongation  and/or TdP  (may precipi[INVESTIGATOR_286737])  
 Hormonal contraception, or hormonal medications used as a hormonal replacement 
therapy for symptoms of menopause  (as these ha ve potential to reduce efficacy of ET)  
 Other investigational and anti -neoplastic therapi[INVESTIGATOR_014]  
[IP_ADDRESS]  Concomitant medications associated with men opausal status  
It is important to consider potential drug -drug interactions when using concomitant 
medications associated with hot flushes and other anticipated symptoms associated with this 
indication/use of ET. Use of systemically administered medication s containing estrogens is 
not allowed (see Section 6.3.3 ). Please see Table 14 -3 in Appendix 2  for further information 
on prohibited concomitant medications.  
[IP_ADDRESS]  Drugs with QT prolongation  
As far as possible avoid co -administering  medications with a “Known”, “Possible” or 
“Conditional” risk of TdP (www.qtdrugs.org)  or any other medication with the poten tial to 
increase the risk of drug -related QT prolongation (e.g. via a potential DDI increasing the 
exposure of ribociclib or the exposure of the QT prolonging drug). If concomitant 
administration of drugs with a known risk of TdP is required and cannot be avoided, ribociclib  
must be interrupted  (see Table 6 -5). If during the course of the study, concomitant 
administration of a drug with “Possible risk ” or “Conditional risk ” of TdP is required, based 
on th e investigator assessment and clinical need, study treatment may be resumed under close 
clinical and ECG monitoring to ensure patient safety. A list of drugs associated with QT 
prolongation and/or TdP is available online (www. qtdrug s.org). Medications with  a known 
risk for QT prolongation are prohibited during study treatment.  
[COMPANY_001]  Confidential  Page 51 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 6.3.4  Other procedures  
Use of AIs may cause decrease in bone mineral density. C onsider bone mineral density 
monitoring  in patients receiving AI s, and appropriate preventive or therapeutic measures for 
osteopenia and osteoporosis  in these patients  per local clinical guidelines . 
Use of letrozole or anastrozole  may cause increase in total blood cholesterol. Consider 
monitoring cholesterol, and taking appropriate preventive or therapeutic measu res in patients 
receiving AIs per local clinical guidelines . 
Please refer to regional prescribing information of specific endocrine agent for additional 
procedures and supportive measures requir ed during administration of ET.  
6.4 Patient numbering, treatment a ssignment or randomization  
6.4.1  Patient numbering  
The study has been closed to enrollment. All randomized patients were unblinded; patients 
randomized to placebo permanently discontinued study treatment and patients randomized to 
ribociclib were offered the option to continue treatment with ribociclib + E T (excluding 
tamoxifen).  
Each patient is identified in the study by a Subject Number (Subject No.), that is assigned 
when the patient is first enrolled for screening and is retained as the primary identifier for the 
patient throughout his/her entire parti cipation in the trial. The Subject No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a 
sequential patient number suffixed to it, so that each subject is numbered uniquely across the 
entire database. Upo n signing the informed consent form, the patient is assigned to the next 
sequential Subject No. available to the investigator through the remote data capture ( RDC ) 
interface.  
The investigator or designated staff will contact [CONTACT_348438] ( IRT) and 
provide the requested identifying information for the patient to register them into the IRT. 
Once assigned, the Subject No. must not be reused for any other subject and the Subject No. 
for that individual must not be changed, even if the pat ient is re -screened. If the patient fails to 
be randomized or start treatment for any reason, the reason will be entered into the Screening 
Disposition page.  
6.4.2  Treatment assignment or randomization  
Since the study has been closed to enrollment and no new pat ients will be randomized, this 
section is no longer applicable.  
Patients will be assigned to one of the two treatment arms ( Section 4.1  and Section 6.1 ) in a 
ratio of 1:1. 
Rand omization will be stratified by  
 Menopausal status: (premenopausal women /men ) vs (postmenopausal women),  
 Stage group (AJCC 8th edition Prognostic Stage Group IIIA) vs (AJCC 8th edition 
Prognostic Stage Groups IIIB/C) vs (residual di sease af ter neoadjuvant chemotherapy),  
[COMPANY_001]  Confidential  Page 52 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  Geographical region: (North America/Europe /Australia ) vs (rest of the world).  
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed fro m patients and investigator staff. A patient 
randomization list will be produced by [CONTACT_6609] a validated system that 
automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the di fferent treatment arms, which in turn are linked to 
medication numbers. A separate medication randomization list will be produced by [CONTACT_348439] a validated system that 
automates the random assignmen t of medication numbers to medication packs containing 
each of the study treatments.  
Prior to dosing, all patients who fulfill all inclusion/exclusion criteria will be randomized via 
IRT to one of the treatment arms. The investigator or his/her delegate wi ll contact  [CONTACT_348440]/exclusion criteria. The IRT will assign a 
randomization number to the patient, which will be used to link the patient to a treatment arm 
and will specify a unique medication number for the first package of ribociclib/placebo  to be 
dispensed to the patient  in combination with ET at Cycle 1 Day 1  no later 3 days after the 
randomization of the patient . The randomization number will not be communicated to the 
caller.  
6.4.3  Treatment blinding  
Since all randomized patients were unblinded , this section is no longer applicable.   
6.5 Study drug preparation and dispensation  
Patients will be provided with an adequate supply of study drug  (ribociclib ) for self -
administration at home, including instructions for administration, until at least their next 
scheduled study visit. Patients will receive ribociclib on an outpatient basis. The investigator 
will provide the patient with instructions for ribocicli b administration according to the 
protocol.  
Letrozole, anastrozole, exemestane and GnRH agonist should be dispensed and administered 
according to local prescribing information and practice.  
The investigator or responsible site personnel must instruct the patient or caregiver to take the 
study drugs as per protocol. Ribociclib and other study treatments  will be dispensed to the 
patient by [CONTACT_178199]. All dosages prescribed to the patient and all dose 
changes during the study must be recorded in the eCRF.  
6.5.1  Study treatment packaging and labeling  
Ribociclib/placebo  will be provided as global clinical blinded supply and will be packed and 
labeled under the responsibility of Novar tis Drug Supply Management  (see Table 6 -7 and 
Table 6 -8). 
Following the protocol amendment 02, only ribociclib will be dispensed to patients.  
Ribocicl ib/placebo packaging has a 2 -part label. A unique medication number is printed on 
each part of this label which corresponds to one of the treatment arms. Responsible site 
[COMPANY_001]  Confidential  Page 53 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 personnel will identify the package(s) to dispense to the patient by [CONTACT_348441] d 
obtaining the medication number(s). Site personnel will add the Patient Number on the label. 
Immediately before dispensing the package to the patient, site personnel will detach the outer 
part of the label from the packaging and affix it to the source document (Drug Label Form) 
for that patient’s unique patient number.  
Medication  labels will be in the local language and comply with the legal requirements of 
each country . They  will include storage conditions  for the drug  and the  medication number  
but no information about the patient . 
Table 6-7 Packaging and labeling  
Study treatments  Packaging  Labeling (and dosing frequency)  
Ribociclib/ placebo  Tablets in bottles  Study drug packaging has a [ADDRESS_432858] access. Upon receipt, the study treatment should be stored 
according to the instructions specified on the drug labels and in the [Ribo ciclib Investigator ’s 
Brochure ]. 
Table 6-[ADDRESS_432859] information  
6.5.3  Study drug compliance and accountability  
[IP_ADDRESS]  Study drug compliance  
Compliance will be assessed by [CONTACT_1755]/or study personnel at each patient visit 
and information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
[COMPANY_001]  Confidential  Page 54 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Accountability Form. This information must be captured in the source document  at each 
patient visit.  
[IP_ADDRESS]  Study drug accountability  
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study treatment in a drug accountability log. Drug accountability will be noted by [CONTACT_348442]. Patients will be asked to return 
all unused study treatment and packaging on a regular basis, at the end of the study or at the 
time of study treatment discontinuation.  
At study close -out, and, as appropriate d uring the course of the study, the investigator will 
return all used and unused study treatment, packaging, drug labels, and a copy of the 
completed drug accountability log  to the [COMPANY_001] monitor or to the [COMPANY_001] address provided 
in the investigator fol der at each site.  
6.5.[ADDRESS_432860] party, as appropriate . Study drug destruction at the investigational site will only be 
permitted if authorized by N ovartis in a prior agreement and if permitted by [CONTACT_427].  
7 Visit schedule and assessments  
7.1 Study flow and visit schedule  
Table 7 -1 lists all of the assessments and indicates with an “X”, the visi ts when they are 
performed. All data obtained from these assessments must be supported in the patient’s source 
documentation.  
The table indicates which assessments produce data to be entered into the clinical database (D) 
or remain in source documents only  (S) (“Category” column). No CRF wil l be used as a 
source document.  
Allowed visit windows are specified as follows:  
 Screening assessments, apart from those listed below, must occur within 28 days prior to 
the randomization as per Table 7 -1. 
 Randomization and Cycle 1 Day 1 should preferably occur on the same day. A maximum 
of a 3 days window between randomization and Cycle 1 Day 1 visit is permitted.  
 For all visits a general ±3 days  visit window is permitted on assessments to take into 
account scheduling over public holidays, if not explicitly specified otherwise.  
 Radiological  and histological assessments must be performed as outlined in Table 7 -1. A 
visit window of ± 2 weeks  is allowed unless otherwise specified.   
 Every effort should be made to follow the schedule outlined in Table [ADDRESS_432861] been randomized.  
[COMPANY_001]  Confidential  Page 55 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Table 7-1 Visit evaluation schedule  
 
Category  
Protocol 
Section  Screening 
phase  Treatment phase  
Ribociclib + endocrine therapy (26 cycles / approx. 24 months)  
Visit Name    [CONTACT_348458] 
1 Cycle 2  Cycles 
3 to 6  Cycles 7 to 26 (every 
3 cycles from C7D1)  End of treatment  Safety follow up  
Study/treatment 
cycle day    -[ADDRESS_432862] dose of 
ribociclib + 30 days  
Screening  
Obtain Study Informed 
Consent  D 7.1.1   X         
IRT Screening (after 
ICF) D 7.1.1   X         
Disposition assessment  
End of phase 
disposition  D 7  X       X  
Patient history  
Demography  D [IP_ADDRESS]   X         
Inclusion/exclusion 
criteria  D [IP_ADDRESS]   X         
Medical history  D [IP_ADDRESS]   X         
Diagnosis, stage and 
grade of cancer  D [IP_ADDRESS]   X         
ER status  D [IP_ADDRESS]   X         
PgR status  D [IP_ADDRESS]   X         
HER2 status  D [IP_ADDRESS]   X         
Prior anti -neoplastic 
therapi[INVESTIGATOR_014]  D [IP_ADDRESS]   X         
Prior/concomitant D [IP_ADDRESS]   Continuous, up to [ADDRESS_432863] dose of ribociclib  
[COMPANY_001]  Confidential  Page 56 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  
Category  
Protocol 
Section  Screening 
phase  Treatment phase  
Ribociclib + endocrine therapy (26 cycles / approx. 24 months)  
Visit Name    [CONTACT_348458] 
1 Cycle 2  Cycles 
3 to 6  Cycles 7 to 26 (every 
3 cycles from C7D1)  End of treatment  Safety follow up  
Study/treatment 
cycle day    -[ADDRESS_432864] dose of 
ribociclib + 30 days  
medications  
IRT Dispensation  
IRT ribociclib  
dispensation  S [IP_ADDRESS]    X  X  X X (every cycle)    
Physical examination  
Physical examination  S [IP_ADDRESS]   X   X  X X X  
Vital signs  D [IP_ADDRESS]   X X X X  X X X  
Weight  D [IP_ADDRESS]   X X X X  X X X  
Height  D [IP_ADDRESS]   X         
Menopausal status assessment  
Menopausal status  D [IP_ADDRESS].5   X Every 12 months or as clinically indicated  
Laboratory assessments  
Hematology  D [IP_ADDRESS].1   X  X X X X X X  
Biochemistry  D [IP_ADDRESS].2   X  X X X X X X  
Coagulation  D [IP_ADDRESS].3   X As clinically indicated    
Urinalysis  D [IP_ADDRESS].[ADDRESS_432865] 
(for women of child 
bearing potential only)  D [IP_ADDRESS].[ADDRESS_432866] 
(for women of child 
bearing potential only)  D [IP_ADDRESS].5    X  X  X X (every cycle)    
[COMPANY_001]  Confidential  Page 57 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  
Category  
Protocol 
Section  Screening 
phase  Treatment phase  
Ribociclib + endocrine therapy (26 cycles / approx. 24 months)  
Visit Name    [CONTACT_348458] 
1 Cycle 2  Cycles 
3 to 6  Cycles 7 to 26 (every 
3 cycles from C7D1)  End of treatment  Safety follow up  
Study/treatment 
cycle day    -[ADDRESS_432867] dose of 
ribociclib + 30 days  
Recurrence assessment  
Clinical evaluation for 
recurrence  D  X After randomization as clinically indicated, or at any time when recurrence is suspected  
Mammography 
(unless bilateral 
mastectomy)  D 7.2.1   X (unless 
done 
within 
previous 
12 months)  As clinically indicated, or at any time when recurrence is suspected  
Radiological 
evaluation (CT, MRI, 
US, PET, bone scan , 
X-ray or 
mammography)  D 7.2.1   If clinically 
indicated  As clinically indicated, or at any time when recurrence is suspected  
Histological (or 
cytological, when 
applicable)  D 7.2.1   If clinically 
indicated  As clinically indicated, or at any time when recurrence is suspected  
Cardiac assessments  
  Single ECG 
(standard 12 -lead) D [IP_ADDRESS]   X  X X  X X (at C7D1 for all 
patients, then assessed 
only if QTcF > 481 
msec during previous 
cycles)  X  
Safety  
Adverse events  D [ADDRESS_432868] dose of ribociclib   
 
[COMPANY_001]  Confidential  Page 58 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  
Category  
Protocol 
Section  Screening 
phase  Treatment phase  
Ribociclib + endocrine therapy (26 cycles / approx. 24 months)  
Visit Name    [CONTACT_348458] 
1 Cycle 2  Cycles 
3 to 6  Cycles 7 to 26 (every 
3 cycles from C7D1)  End of treatment  Safety follow up  
Study/treatment 
cycle day    -[ADDRESS_432869] dose of 
ribociclib + 30 days  
Study Drug administration  
Ribociclib  D 6   Day 1 -21 daily, Day 22 -28 off    
Adjuvant endocrine 
therapy (ET)  D 6  letrozole / anastrozole / exemestane daily, GnRH agonist (if indicated) every 4 weeks  
Discontinuation  
IRT Discontinuation 
ribociclib  S 7.1.3          X  
Subsequent anti -
neoplastic therapi[INVESTIGATOR_014] 
(medication, surgery, 
radiotherapy)  D 7.1.5          X 
[COMPANY_001]  Confidential  Page 59 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 7.1.1  Screening  
After signing the study ICF, the screening assessments will be done within 1 to 28 days prior 
to randomization (see Table [ADDRESS_432870] of assessments to be performed).  
Re-screening of patients is only al lowed once  per patient if the patient was not registered as 
entering the treatment phase before (i.e. IRT randomization). In this case the Subject Number 
assigned to the patient initially will be used and the patient will be identified with this number 
throughout his/her entire participation to the study.  If patient has been randomized, re -
screening of patient is not allowed.  
In case rescreening occurs, all evaluations re -assessed should meet the eligibility criteria. A 
new informed consent form must be sig ned only if there is an interruption in the patient’s 
eligibility evaluation and the investigator chooses to re -screen the patient following screen 
failure; the 28 day screen period does not apply to the informed consent process. If a new 
informed consent form is signed, AEs and medical history will be assessed relative to the new 
informed consent date.  
For laboratory evaluations used to determine eligibility, a repeated evaluation within the 
screening window is permitted for screening results out of the de fined range before screen 
failing the patient. If the repeated laboratory result meets the criteria, that result may be used 
to determine eligibility. If the repeated laboratory result does not meet the criteria, the patient 
will be considered a screening failure. For details of assessments, see Table 7 -1. 
A mandatory archival paraffin tumor tissue (tumor blocks or slides with tumor tissue) from 
surgical specimen should be shipped to the designated laboratory before the planned 
randomization date  (see Section [IP_ADDRESS].1 ). 
Assessments of patient reported outcomes during the Screening should be collected prior to 
any clinical assessments, drug dosing or diagnostic testing.  
Any imaging assessments , if clinically indicated, are to be done  during Screening period (i.e. 
within 28 days prior to randomization ). 
An additional biomarkers informed consent will be available to the patient for optional 
participat ion.  
[IP_ADDRESS]  Eligibility screening  
Following registering in the IRT for screening, patient eligibility will be checked once all 
screening procedures are completed. The eligibility check will be embedded in the IRT 
system. Please refer and comply with detailed gui delines in the IRT manual.  
[IP_ADDRESS]  Information to be collected on screening failures  
Patients who sign an informed consent but fail to be randomized  for any reason will be 
considered a screen failure. The reason for not being started on treatment will be entered o n 
the Screening Phase Disposition Page. The demographic information, informed consent, 
Inclusion/Exclusion pages and, if applicable, withdrawal of informed consent must also be 
completed for Screen Failure patients. No other data will be entered into the c linical database 
[COMPANY_001]  Confidential  Page 60 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 for patients who are screen failures, unless the patient experienced a n SAE  during the 
Screening Phase (see Section 8  for SAE reporting details).  
If a screen failure patient experiences an AE which does not meet the SAE criteria, details 
about the AE will be recorded only in the investigator’s source documents. In case of an SAE 
after signing of main study informed consent, data must be recorded on both the AE and SAE 
forms.  
If the patien t fails to be randomized, the IRT must be notified within 2 days of the screen fail 
that the patient was not randomized.  
[IP_ADDRESS]  Patient demographics and other baseline characteristics  
The data that will be collected on patient characteristics at screening include s: 
 Demography (Date of birth or partial date of birth and initials (where permitted  by [CONTACT_13125] ), sex, race, ethnicity) . 
 Medical history (e.g., important medical, surgical, and allergic conditions from the 
patient’s medical history which could hav e an impact on the patient’s evaluation) / current 
medical conditions (e.g., all relevant current medical conditions which are present at the 
time of signing informed consent). Ongoing medical conditions, symptoms and disease 
which are recorded on the Medi cal History eCRF should include the toxicity grade  per 
CTCAE v 4.03 . 
 ER, PgR , HER2 , histopathological grade  (the Nottingham combined histologic grade  
(Elston and Ellis 2002 )) and, if available, Ki -67, genomic subtype and results of any of the 
genomic  predictive and prognostic  tests. 
 Diagnosis and extent of cancer (including histology and AJCC 8th edition Anatomic 
(“TNM staging”) and Prognostic Stage Groups  (see Table 14 -1 and Table 14 -2 in 
Appendix 1 ): 
 Anatomic Stage Group at time of diagnosis, i.e. before  the curative  surgery , if 
available  
 Anatomic and Prognostic Stage Groups  at the study entry, i.e.  after the curative 
surgery : 
 for patients who received adjuvant chemotherapy reporting of both Anatomical 
Stage Group  and Prognostic Stage Group is required  
 for patients who re ceived neoadjuvant chemotherapy  reporting of  Prognostic 
Stage Group  is not required . 
 All prior anti -neoplastic therapi[INVESTIGATOR_348393] , and chemo -, biologic -, 
immunologic - and radiation -therapi[INVESTIGATOR_348394]  (ovarian suppression 
for fertility preservation by [CONTACT_348443] -neoplastic therapy) . 
 All medications and significant non -drug therapi[INVESTIGATOR_14939] [ADDRESS_432871] be recorded on the Prior and Concomitant medication or 
Surgical and medical procedures eCRF page and updated on a continual basis if there are 
any new changes to the medications.  
[COMPANY_001]  Confidential  Page 61 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  Patient -reported outcome questionnaires (EORTC QLQ -C30, EORTC QLQ -BR23  (for 
women only) , EQ-5D-5L, and HADS (See Section 7.2.5 ). 
Furthermore the following assessments will be performed:  
 Vital signs  
 Height, weight  
 Physical examination  
 ECOG Performance Status  
 Menopausal status  (for women)  
 Laboratory evaluations (hematology, coagulation , chemistry, urinalysis , pregnancy test for 
women  of child bearing potential ) 
 Triplicate ECG  
 Clinical evaluation for recurrence and if clinically indicated, radiological and/or 
histological/cytological assessments.   
 A mandatory archival paraffin tumor tissue  (tumor block or tumor slides with tumor tissue)  
from surgical specimen . 
7.1.2  Treatment period  
Patients will be randomized using menopausal status, stage  group  (i.e., Prognostic Stage 
Groups (see Table 14 -2 in Appendix 1 ) for patients who were treated with adjuvant 
chemotherapy, or patients with residual disease in lymph nodes and breast tissue after 
neoadjuvant chemotherapy)  and geographical region for stratification. Study treatment should 
be started as soon as possible and no later than 3 days after the randomization of the patient.  
The study has been c losed to enrollment. All randomized patients were unblinded; patients 
randomized to placebo permanently discontinued study treatment and patients randomized to 
ribociclib were offered the option to continue treatment with ribociclib + ET (excluding 
tamoxif en) for a maximum of 26 cycles (approximately 24 months) of ribociclib or until first 
recurrence, intolerable toxicity, withdrawal of consent by [CONTACT_102], patient is lost to follow 
up, death, discontinuation from the study treatment due to any other rea son, or the sponsor 
terminates the study , whichever is earlier . Treatment ends with the last dose of ribociclib.  
For details of assessments, see Table [ADDRESS_432872] make a 
reasonable effort (e.g. telephone, e -mail, letter) to understand the primar y reason for this 
decision and record this information in the patient’s chart and on the appropriate CRF pages.  
They may be considered withdrawn if they state an intention to withdraw, fail to return for 
visits, or become lost to follow -up for any other re ason.  
The investigator  should discontinue  study treat ment for a given  patient  if, he/she  believes  
that continu ation would be  detrimental  to the patie nt’s well-being.  
[COMPANY_001]  Confidential  Page 62 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 In addition to mandatory discontinuation reasons for investigational treatment (ribociclib)  
listed in  Section 6.[ADDRESS_432873]  also be discontinued  under  the following  
circu mstance s: 
 Pregnancy  
 Lactation  
 Death  
 Subject/Guardian decision  
 Adjustments to study treatment due to toxicity that result in treatment discontinuation ( see 
Section 6.2 ) 
 Use of prohibited  medication  (see Section 6.3 ). 
 Any other  protocol  deviation  that results  in a significant risk to the patient’s  safety. 
The appr opriate per sonnel fr om the site and [COMPANY_001] will asse ss whether study  treatment 
should be discontinued for any patient  whose treat ment code  has been  broken  inadvertently  for 
any reason.  
Patie nts who discontinue  study  treatment should NOT  be considered withdrawn from  the 
study.  They  should  return  for the assess ments indicated in  Section 7.2  for an EOT visit . If 
they fail to return for these  assess ments for unknown  reasons, every  effort  (e.g. telephone, 
email, letter)  shou ld be made to contact  [CONTACT_348444] 7.1.[ADDRESS_432874] the IRT to register  the patient’s  discontinuation  from 
study  treatment within 2 days of the EOT visit . 
Patients who discontinue study treatment should undergo an End of Treatment (EOT) visit 
followed by a 30 day safety follow -up. At EOT visit, all the assessments as listed in Table 7 -1 
will be performed. If the decision to discontinue the patient occurs at a regularly scheduled 
visit, that visit may serve as the EOT visit rather than having the patient return for an 
additional v isit. 
[IP_ADDRESS]  Withdrawal of consent  
Patients  may voluntarily withdraw  consent  to participate in  the study  for any reason  at any 
time. Withdrawal of  consent  occurs  only when  a patient  does not want  to participate in the 
study  any longer,  and does not want  any further visits  or assess ments, and does not want  any 
further  study  related  contact.  
[COMPANY_001]  will continue  to retain  and use all research results  that have already  been  collected 
for the study  evaluation.  All biological sa mples that have already  been collected may be 
retained  and analyzed  at a later date (or as required  by [CONTACT_427]).  
If a patient  withdraws  consent,  the investigator  should  make a reasonable effort  (e.g. telephone,  
e-mail, lette r) to understand t he primary reason for this de cision and rec ord this in formation.  
Study t reatment must be discontinued  and no further assess ments conducted.  
Further  attempts to  contact  [CONTACT_348445]. 
[COMPANY_001]  Confidential  Page 63 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 7.1.[ADDRESS_432875] the 
patient should be documented in the source documents (e.g., dates of telephone calls, 
registered letters, etc.) . 
7.1.5  Follow -up phase  
[IP_ADDRESS]  Post treatment follow up for recurrence  
Since the study will end after the completion of safety follow up within [ADDRESS_432876]-treatment follow -up phase assessments will end study participation with  the protocol 
amendment 02.  
[IP_ADDRESS]  Survival follow -up 
Since the study will end after the completion of safety follow -up assessment within [ADDRESS_432877] to f ollow-up 
For patie nts whose  status is  unclear  because  they fail  to appear  for study visits without  stating 
an intention  to withdraw consent,  the investigator should  show  "due diligence"  by [CONTACT_15027], fa mily or  family physician  as agreed in  the infor med consent  and by [CONTACT_348446],  e.g. dates  of telephone  calls, 
registered letters, etc. A patie nt should not be considered  lost to follow -up until due diligence 
has been  completed. Patients  lost to follow  up should  be recorded  as such on the appropriate 
CRF. 
7.2 Assessment types  
7.2.1  Recurrence assessments  
Recurrence will be assessed by [CONTACT_348447], as clinically indicated, or at any time when recurrence is suspected .  
Any of the following radiological assessments may be used for evaluation of suspi[INVESTIGATOR_348395] : 
[COMPANY_001]  Confidential  Page 64 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  Chest, abdomen and pelvis computer tomography ( CT) or magnetic resonance imaging 
(MRI ) 
 Brain CT or MRI  
 Whole body bone scan  (bone scintigraphy)  
 Localized bone CT, MRI or x -ray, for any lesions identified on the whole body bone scan 
that are not visible on the chest, abdomen and pelvis CT or MRI  
 CT or MRI of other sites (e.g., neck , extremities ) 
 Ultrasound  
 Fludeoxyglucose (18F) positron emission tomography ( FDG -PET) 
 Mammography  
Biopsy or cytology maybe used to confirm recurrence histologica lly (or cytological ly), unless 
the biopsy poses an unacceptable risk to the patient. Recurrence will be reported in eCRF. 
Treatment with ribociclib + ET will be discontinued at time of recurrence (any type of 
recurrence - either local, regional, distant, cont ralateral non -invasive breast cancers or  second -
primary invasive non -breast cancer).   
7.2.2   Safety and tolerability assessments  
Safety of patients  will be monitored by [CONTACT_15033],  height  and weight,  
vital signs,  ECG,  laborator y assessments  including  hematolog y, chemistr y, and coagulation  as 
well as collecting of the AEs at every visit. For details on AE collection and reporting, see 
Section 8 . 
The ECOG Performance Status and patient -reported outcomes are no longer collected 
following the protocol amendment 02.  
[IP_ADDRESS]  Physical examination  
The physical examination comprises a total body examination that should include: general 
appearance, skin, neck (including thyroid), eyes, ears, nose , throat, lungs, heart, abdomen, 
back, lymph  nodes, extremities, vascular and neurological review. If indicated, rectal, external 
genitalia, breast and pelvis exams will be performed. Information about the physical 
examination must be present in the source  documentation at the study site. Physical 
examination is to be performed according to the visit schedule as outlined in Table [ADDRESS_432878] be 
included in the Medical History page on the patient’s CRF. Significant new findings that 
begin or worsen after informed consent must be recorded on the Adverse Event page of the 
patient’s CRF.  
[IP_ADDRESS]  Vital signs  
Vital signs (body temperature, pul se rate, blood pressure) will be monitored as per the visit 
schedule (see Table 7 -1). Blood pressure (systolic and diastolic) and pulse should be 
measured after the patient has been sitting for approxima tely five minutes.  
[COMPANY_001]  Confidential  Page 65 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 [IP_ADDRESS]  Height and weight  
Height will be measured at screening  only. 
Weight  will be measured at screening and at subsequent time points as specified in Table 7 -1. 
[IP_ADDRESS]  Performance status  
Following the protocol amendment 02, the performance status assessment is no longer 
performed.  
  
[IP_ADDRESS]  Laboratory evaluations  
Following the protocol amendment 02, all clinical laboratory analyses (Hematology, 
Chemistry, Coagulation, Urinalysis, and serum pregnancy test) will be  performed by [CONTACT_348448] (see Table 7 -3). The investigator is responsible for reviewing all laboratory 
reports for patients in the study and evaluating any abnormalities for clinic al significance.  
For assessment of patients’ eligibility to the study, only laboratory results from the 
central laboratory will be used  (except for FSH and estradiol for determination  / 
confirmation of menopausal status) . 
Unscheduled local laboratory assessments may be performed if medically indicated to 
document a (potential) AE.  
At any time during the study  up to safety follow -up, abnormal laboratory parameters which 
are clinically relevant and require an action to be ta ken with study treatment (e.g., require 
dose modification and/or interruption of study treatment, lead to clinical symptoms or signs, 
or require therapeutic intervention), whether specifically requested in the protocol or not, will 
be recorded on the AE eC RF page. The severity of laboratory data will be graded using the 
Common Terminology Criteria for Adverse events (CTCAE) version 4.03. Additional 
analyses are left to the discretion of the investigator.   
Table 7-2 Clinical laboratory parameters collection plan  (all are done locally with 
the protocol amendment 02)  
Test Category  Test Name  
[CONTACT_348459] (WBC) with differential (neutrophils, lymphocytes,  monocytes, 
eosinophils, and basophils), bands, differential other, hemog lobin and platelet count  
Biochemistry  Sodium, potassium, uric acid, urea or BUN, creatinine, glucose (fasting only if non -fasting 
is out of range), calcium, magnesium, phosphorous and albumin.  
AST (SGOT), ALT (SGPT), total bilirubin, direct bilirubin and alkaline phosphatase,  
Amylase, lipase and LDH , total cholesterol  
Coagulation  aPTT , International normalized ratio [INR]  
Urinalysis  Macroscopic Panel (Dipstick) (Color, Bilirubin, Blood, Glucose, Ketones, Leukocytes  
esterase, Nitrite, pH, Protein, Specific Gravity, Urobilinogen)  
If there are any significant findings on the dipstick then a microscopic evaluation should  
be measured: Microscopic Panel (WBC and RBC sediments, Casts, Cry stals, Bacteria,  
Epi[INVESTIGATOR_1663])  
Other Tests  Pregnancy test (serum)  
[COMPANY_001]  Confidential  Page 66 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 [IP_ADDRESS].1  Hematology  
Hematology tests are to be performed according to the Visit Schedule outlined in Table 7 -1. 
For details of the Hematology panel see Table 7 -2. 
Hematology should be assessed on the actual scheduled day, even if study drug is being 
withheld.  
[IP_ADDRESS].2  Biochemistry  
Biochemistry tests are to be performed according to the Visit Schedules outlined in  Table 7 -1. 
For details of the Biochemistry panel see Table 7 -2. Biochemistry should be assessed on the 
actual scheduled day, even if study drug is being withheld.  Estimate of GFR (via estimated 
creatinine clearance rate) will be done centrally using Cockcroft -Gault formula  
 
[IP_ADDRESS].[ADDRESS_432879] ≤ 1.5.  
Coagulation will be performed by [CONTACT_348449] 02 . 
[IP_ADDRESS].4  Urinalysis  
Urinal ysis is to be performed  according  to the Visit  Schedules  outlined  in Table 7 -1. For 
details of the urina lysis panel see Table 7 -2. 
[IP_ADDRESS].5  Pregnancy and assessments of fertility  
FSH, estradiol, serum and urine pregnancy tests (patients who have undergone a hysterectomy 
do not need pregnancy tests performed) are to be performed according to the Visit Schedules 
outlined in Table [ADDRESS_432880] should be performed for women of child 
bearing potential only, while at Cycle 1 day 1 and at each cycle, urinary pregnancy t ests are 
sufficient.  
FSH and estradiol will be done locally at screening for eligibility and for confirmation of the 
menopausal status.  Menopausal status will be recorded in eCRF.  

[COMPANY_001]  Confidential  Page 67 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Table 7-[ADDRESS_432881] Name  
[CONTACT_348460], estradiol for confirmation of menopausal status (pre - / post -), urine pregnancy . 
Note: FSH and estradiol are not recorded in eCRF, but used  to determine menopausal 
status  
[IP_ADDRESS]  Cardiac assessments  
[IP_ADDRESS].1  Electrocardiogram (ECG)  
Standard single 12 lead ECG assessments will be performed (in the supi[INVESTIGATOR_2547])  after the 
patient has been resting for 5 -10 minutes prior to each time point indicated in Table 7 -4 below. 
ECG assessments are to be done prior to blood collection sampling (if applicable ). Following 
the protocol amendment 02, all ECG will be performed and assessed locally.  
Table 7-4 ECG collection plan  (all ECGs are performed and assessed  locally 
with the protocol amendment 02)  
Cycle  Patients  Day Time  ECG Type  
Screening  All -[ADDRESS_432882] -dose ( ± 15 min)  Single [ADDRESS_432883] cycle  For patients with QTcF ≥ [ADDRESS_432884] be recorded on the appropriate eCRF  
The QTcF values using Fridericia’s correction  (formula is  provided  below)  will be assessed 
locally following  the protocol amendment 02 . 
 
Eligibility will be based on the average of the triplicate ECGs conducted at screening.   
If any of the readings include a new clinically -relevant abnormal ECG or a QTcF value of ≥ 
[ADDRESS_432885] ECG assessment may be 
performed at any time during the study at the discretion of the investigator.  

[COMPANY_001]  Confidential  Page 68 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 All ECGs including unscheduled ECGs with clinically relevant findings, collected during the 
study should be assessed locally . Each ECG tracing should be labeled with the study number, 
patient number, date, and kept in the source documents at the study site. Clinically significant 
ECG abnormalities present at screening when the patient signed informed  consent should be 
reported on the Medical History CRF page. New or worsened clinically significant findings 
occurring after informed consent must be recorded on the Adverse Events CRF page.  
7.2.3  Biomarkers  
Following  the protocol amendment 02, tumor and blood s amples collection for biomarkers 
assessments  are no longer performed.  
7.2.4  Resource utilization  
Following  the protocol amendment 02, collection of data for healthcare resource utilization is 
no longer performed.  
7.2.5  Patient reported outcomes  
Following  the protocol amendment 02, collection of data for patients reported outcomes is no 
longer performed.  
8 Safety monitoring and reporting  
8.1 Adverse events  
8.1.1  Definitions and reporting  
An adverse event (AE) is defined as the appearance of (or worsening of any pre -exist ing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained.  
Abnormal laboratory values or test results occurring after informed consent constitute AEs 
only if they induce clinical sign s or symptoms, are considered clinically significant, require 
therapy (e.g., hematologic abnormality that requires transfusion or hematological stem cell 
support), or require changes in study treatment (s). 
AEs that begin or worsen after informed consent sh ould be recorded in the Adverse Events 
CRF. Conditions that were already present at the time of informed consent should be recorded 
in the Medical History page of the patient’s CRF. A E monitoring should be continued for at 
least 30 days (or 5 half -lives, w hichever is longer) following the last dose of study treatment. 
AEs (including lab abnormalities that constitute AEs) should be described using a diagnosis 
whenever possible, rather than individual underlying signs and symptoms. When a clear 
diagnosis cann ot be identified, each sign or symptom should be reported as a separate A E. 
AE will be assessed and graded according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version  4.03.  
If CTCAE grading does not exist for an adverse event, the sever ity of mild, moderate, severe, 
and life -threatening, death related to the AE corresponding respectively to Grades  1 - 5, will 
[COMPANY_001]  Confidential  Page 69 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 be used. Information about any deaths (related to an A E or not) will also be collected th rough 
a Death form.  
The occurrence of AEs should be sought by [CONTACT_105] -directive questioning of the patient (subject) 
during the screening process after signing informed consent and at each visit during the study. 
AE also may be detected when they are volunteered by [CONTACT_102] (subject) during the 
screening process or between visits, or through physical examination, laboratory test, or other 
assessments. As far as possible, each AE should be evaluated to determine:  
 The severity grade (CTCAE v4.03 Grade s 1-5) 
 Its duration (Start and end dates)  
 Its relationship to the study treatment . Reasonable possibility that AE is related:  
 No (i.e. not treatment -related) ; 
 Yes, investigational treatment  (i.e. related to treatment with ribociclib) ; 
 Yes, other study treatment ( i.e. related to  treatment with ET); 
 Yes, both and/or indistinguishable  (i.e. related to treatment with both ribociclib and 
ET, or indistinguishable)  
 Action taken with respect to study or investigational treatment (none, dose adjusted, 
temporarily interrupted, permanently discontinued, unknown, not applicable)  
 Whether medication or therapy was given (no concomitant medication/non -drug therapy, 
concomitant medication/non -drug therapy)  
 Whether it is serious, where a n SAE is defined as in Section 8.2.[ADDRESS_432886] been met  
 Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequ elae, fatal, unknown)  
If the event worsens the event should be reported a second time in the CRF noting the s tart 
date when the event worsens in toxicity. For all AEs, if improvement to a lower grade is 
determined a new entry for this event should be reported in the CRF noting the start date 
when the event improved from previous grade . 
All AEs should be treated a ppropriately. If a concomitant medication or non -drug therapy is 
given, this action should be recorded on the Adverse Event CRF.  
Once an AE is detected, it should be followed until its resolution or until it is judged to be 
permanent, and assessment should  be made at each visit (or more frequently, if necessary) of 
any changes in severity, the suspected relationship to the study treatment, the interventions 
required to treat it, and the outcome.  
Recurrence of malignancy (including  resulting in  fatal outcome s), if documented by [CONTACT_348450] (for example, confirmed recurrence per STEEP Criteria  is reported ), 
should not be reported as an AE, including SAE . 
AEs separate from the progression of malignancy (example, deep vein thrombosis at the time 
of progression or hemoptysis concurrent with finding of disease progression) will be reported 
as per usual guidelines used for such events with proper attribution regarding relatedness to 
the drug.  
[COMPANY_001]  Confidential  Page 70 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 8.1.[ADDRESS_432887] abnormalities  
[IP_ADDRESS]  Definitions and reporting  
Labo ratory abnormalities that constitute an A E in their own right (are considered clinically 
significant, induce clinical signs or symptoms, require concomitant therapy or require changes 
in study treatment), should be recorded on the Adverse Events CRF. Whene ver possible, a 
diagnosis, rather than a symptom should be provided (e.g. anemia instead of low hemoglobin). 
Laboratory abnormalities that meet the criteria for A Es should be followed until they have 
returned to normal or an adequate explanation of the abn ormality is found. When an abnormal 
laboratory or test result corresponds to a sign/symptom of an already reported AE, it is not 
necessary to separately record the lab/test result as an additional event.  
Laboratory abnormalities, that do not meet the defin ition of an AE, should not be reported as 
AEs. A Grade 3 or 4 event (severe) as per CTCAE does not automatically indicate a SAE 
unless it meets the definition of serious as defined below and/or as per investigator’s 
discretion. A dose hold o f medication fo r the lab abnormality may be required by [CONTACT_348451], by [CONTACT_108], be an AE and must be reported as 
such.  
8.1.[ADDRESS_432888] (AESI) are defined as events (s erious or non -serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitoring and rapid communication by [CONTACT_64104]. Such events may require furthe r investigation in order to ch aracterize and 
understand them.  
AESIs  are defined on the basis of an ongoing review of the safety data. AESIs are discussed 
in detail in the [Ribociclib  Investigator ’s Brochure ]. 
8.2 Serious adverse events  
8.2.1  Definitions  
Serious adverse event (SAE) is defined as one of the following:  
 Is fatal or life -threatening  
 Results in persistent or significant disability/incapacity  
 Constitutes a congenital anomaly/birth defect  
 Is medically significant, i.e., defined as an event that jeopardiz es the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above  
 Requires inpatient hospi[INVESTIGATOR_3850],  
Note that hospi[INVESTIGATOR_348396] s: 
 Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition . 
 Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsen ed since signing the informed consent . 
[COMPANY_001]  Confidential  Page 71 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
  Social reasons and respi[INVESTIGATOR_064]’s 
general condition . 
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_348397] e vent not fulfilling any of the definitions of a SAE given above is 
not a n SAE . 
8.2.[ADDRESS_432889] be reported as follo w-up to the original epi[INVESTIGATOR_5319] 24 
hours of the investigator receiving the follow -up information. An SAE occurring at a different 
time interval or otherwise considered completely unrelated to a previously reported one 
should be reported separately as a  new event.  
Any SAEs experienced after the 30 day safety evaluation follow -up period should be reported 
to [COMPANY_001] within 24 hours of learning of its occurrence if the investigator suspects a causal 
relationship to the study treatment . 
Information about a ll SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each  
specific study treatment (if there is more than one study treatment), complete the SAE Report 
Form in English, and submit the completed form within [ADDRESS_432890] as the original SAE Report.  Each re -
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued or withdrew from study part icipation.  
If the SAE is not previously documented in the [Investigator’s Brochure ] or Package Insert 
(new occurrence) and is thought to be related to the [COMPANY_001] study treatment, an oncology 
[COMPANY_001] Chief Medical Office  and Patient Safety  (CMO &PS) department associate may 
urgently require further information from the investigator for Health Authority reporting. 
[COMPANY_001] may need to issue an Investigator Notification (IN), to inform all investigators 
involved in any study with the same drug that this  SAE has been reported. Suspected 
Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the 
competent authorities and relevant ethics committees in accordance with Directive 
2001/20/EC or as per national regulatory requirements in  participating countries.  
8.[ADDRESS_432891] been unblinded.  
[COMPANY_001]  Confidential  Page 72 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 8.[ADDRESS_432892] be reported to  [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary termination, 
details of the birth, and the presence or absence of any birth defects, congenital abnormalit ies, 
or maternal and/or newborn complications.  
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_36926][INVESTIGATOR_066] (DS&E). 
Pregnancy follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the investigational  any pregnancy outcome. Any SAE 
experienced during pregnancy must be reported on the SAE Report Form.  
Pregnancy outcomes should  be collected for the female  partners of any males who took study 
treatment in this study. Consent to report information regarding these pregnancy outcomes 
should be obtained from the mother.  
8.5 Warnings and precautions  
No evidence available at the time of the approval of this study pro tocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [Investigator 
Brochure ]. Additional safety information collected between IB updates will be communicated 
in the form of Investigator Notifications . This information will be included in the patient 
informed consent and should be discussed with the patient during the study as needed.  
8.6 Data Monitoring Committee  
The study  enrollment was early  closed. All randomized patients were unblinded. After the 
unblinding, the [COMPANY_001] Clinical Trial Team will be responsible for reviewing safety data and 
conducting all analysis( -es) as defined in the protocol.  
8.[ADDRESS_432893] of the following:  
What pr otected health information (PHI) will be collected from subjects in this study  
Who will have access to that information and why  
Who will use or disclose that information  
The rights of a research subject to revoke their authorization for use of their PHI.  
[COMPANY_001]  Confidential  Page 73 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safety information (e.g. has the 
subject experienced any new or worsened AEs) at the end of their scheduled study period.  
The data collection system for this study uses b uilt-in security features to encrypt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually assigned 
user identification co des and passwords, made available only to authorized personnel who 
have completed prerequisite training.  
Prior to entering key sensitive personally identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify t hat this data is allowed to be collected. If 
the site indicates that country rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact d ate of birth) to establish that the subject satisfies protocol age requirements 
and to enable appropriate age -related normal ranges to be used in assessing laboratory test 
results.  
9.2 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study, the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.  
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information , laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent for m (a 
signed copy is given to the patient).  
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informe d consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency of the source data with the 
CRFs are performed according to the study -specific monitoring plan.  
9.3 Data collection  
Following the protocol amendment 02, laboratory and ECG data will be collected and 
performed locally at the sites; data will be entered into the eCRF. PRO data will not be 
collected any longer. Blood and tumor samples for laboratory data and biomarker assessments 
will no longer be collected.  
[COMPANY_001]  Confidential  Page 74 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by [CONTACT_5374] (eCRF). The eCRFs 
have been built using fully validated secure web -enabled s oftware that conforms to [ADDRESS_432894] been trained. Automatic validation programs check for data discrepancies in the 
eCRFs and, allow modification or verifi cation of the entered data by [CONTACT_6649].  
The Principal Investigator [INVESTIGATOR_348398], accurate, and that entry and updates are performed in a timely manner.  
Blood and tumor samples for lab oratory data and biomarkers assessments will be collected by 
[CONTACT_348452]. The laboratory 
results and IRT data will be sent electronically to [COMPANY_001]. ECG data will be collected at the 
sites a nd the data will be transmitted to a designated CRO for centralized analysis, as well as 
further processing. PRO data will be recorded by [CONTACT_348453]. The device will be programmed to ensure that all relevant 
observations are recorded.  
9.4 Database management and quality control  
For studies using eCRFs, [COMPANY_001] personnel (or designated CRO) will review the data entered 
by [CONTACT_5375]. Electronic data queries sta ting the 
nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC system. Designated 
investigator site staff are required to respond promptly to queries and to make any necessary 
changes to the data.  
Concomitant treatments and prior medications entered into the database will be coded using 
the WHO Drug Reference List, which employs the Anatomical Therapeutic Chemical 
classification system. Medical history/current  medical conditions and AEs will be coded using 
the Medical Dictionary for Regulatory Activities (MedDRA) terminology.  
Samples and/or data  (e.g. biomarkers, ECG, safety samples)  will be processed centrally and 
the results will be sent electronically to [COMPANY_001] (or a designated CRO).  PRO data collected 
using an electronic tablet device will be documented into a separate study -specific database 
supplied and managed by a designated  vendor. The PRO database will be accessible to study 
sites and [COMPANY_001] personnel (or a designated CRO) for data management. All PRO data will 
be sent electronically to [COMPANY_001] personnel (or a designated CRO).   
Following the protocol amendment 02, PRO da ta will not be recorded as this assessment is no 
longer required. Blood and tumor samples for laboratory data and biomarker assessments will 
no longer be collected.  Randomization codes and data about all study treatments dispensed to 
the patient and all IR T assigned dosage changes will be tracked using an Interactive Response 
Technology. The system will be supplied by a vendor(s), who will also manage the database. 
The data will be sent electronically to [COMPANY_001] personnel (or designated CRO).  
At the conclu sion of the study, the occurrence of any emergency code breaks will be 
determined after return of all code break reports and unused drug supplies to [COMPANY_001] 
personnel (or designated CRO). The occurrence of any protocol violations will be determined. 
[COMPANY_001]  Confidential  Page 75 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 After  these actions have been completed and the data has been verified to be complete and 
accurate, the database will be declared locked and the treatment codes will be unblinded and 
made available for data analysis. Authorization is required prior to making an y database 
changes to locked data, by [CONTACT_348454].  
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper co pi[INVESTIGATOR_5322].  
[ADDRESS_432895]  dose of ribociclib.  
No analyses for statistical inference is planned. Descriptive summaries of key safety and 
baseline characteristics will be provided. These include summaries of treatment duration 
exposure, adverse events, labs , and ECG  findings . The ef ficacy data collected will be 
summarized via listings. The details are described in the statistical analysis plan.   
10.1 Interim analysis  
Not applicable  
10.2 Sample size calculation  
Not applicable  
11 Ethical considerations and administrative procedures  
11.1 Regulatory and ethical compliance  
This clinical study was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 20 01/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.  
11.2 Responsibilities of the investigator and IRB/IEC/REB  
The protocol and the proposed informed consent form must be reviewed and a pproved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study start. Prior to study start, the investigator is 
required to sign a protocol signature [CONTACT_5389]/her agreem ent to conduct the study 
in accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality Assurance representa tives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs and regulatory authorities as required.  
[COMPANY_001]  Confidential  Page 76 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 11.3 Informed consent procedures  
Eligible patients may only be included in the study after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/R EB-approved informed consent , or, if incapable of 
doing so, after such consent has been provided by a legally acceptable representative of the 
patient. In cases where the patient’s representative gives consent, the patient should be 
informed about the stud y to the extent possible given his/her understanding. If the patient is 
capable of doing so, he/she should indicate assent by [CONTACT_348455] a separate assent form).  
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documented in the patient source documents. The date when a subject’s Informed 
Consent was actually obtained will be captured in their CRFs.  
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study and complies with the ICH GCP 
guideline and regulatory requirement s. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/IEC/REB approval.  
Women of child bearing pote ntial should be informed that taking the study drug may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order 
to participate in the study they must adhere to the contraception requirement for the duration 
of the study. If there is any question that the patient will not reliably comply, they should not 
be entered in the study.  
Additional consent form  
Sub-studies and studies with an optional Exploratory Biomarker component will have a 
separate consent form cove ring those studies  (See Section [IP_ADDRESS].1  for pharmacogenetic 
informed consent details) . This form will be adapted for each Study based on a standard 
template used globally for all Studies. These informed consent forms will be submitted for 
ethical approval together with the Study Protocol and the main informed consent form of the 
Study. If a subject opts not to participate in the optional assessments, this in no way affects 
the subject’s ability t o participate in the main research study.  
11.4 Discontinuation of the study  
[COMPANY_001] reserves the right to discontinue this study under the conditions specified in the 
clinical study agreement. Specific conditions for terminating the study are outlined in Section 
4.4. 
11.5 Publication of study protocol  and results  
[COMPANY_001] is committed to following high ethical standards for reporting study results for its 
innovative medicine, including the timely communication and publication of clinical trial 
results, whatever their outcome.  [COMPANY_001] assures that the key design elements of this protocol 
will be posted on the publicly accessible database, e.g. www.clinica ltrials.gov before study 
[COMPANY_001]  Confidential  Page 77 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 start. In addition, results of interv entional clinical trials in adult patients are posted  on 
www.novartisclinicaltrials.com,  a publicly accessible database of clinical study results within 
1 year of  study completion (i.e., last patient last visit ( LPLV )), those for interventional clinical 
trials involving pediatric patients withi n 6 months  of study completion.  
[COMPANY_001] follows the ICMJE authorship guidelines (www.icmje.org) and other specific 
guidelines of the journal or congress to which the publication will  be submitted.  
Authors will not re ceive remuneration for their writing of a publication, either directly from 
[COMPANY_001] or through the professional medical writing agency.  Author(s) may be requested to 
present poster or oral presentation at scientific congress; however, there will be no 
honorarium provided for such presentations.  
As part of its commitment to full transparency in publications, [COMPANY_001] supports the full 
disclosure of all funding sources for the study and publications, as well as any actual and 
potential conflicts of interest of financial and non -financial nature by [CONTACT_15064], including 
medical writing/editorial support, if applicable.  
For the [COMPANY_001] Guidelines for the Publication of Results from [COMPANY_001] -sponsored Research, 
please refer to www.novartis.com.  
11.[ADDRESS_432896] keepi[INVESTIGATOR_348399], in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protectio n of confidentiality of subjects. As part of participating in a 
[COMPANY_001] -sponsored study, each site will permit authorized representatives of the sponsor(s) 
and regulatory agencies to examine (and when required by [CONTACT_1289], to copy) clinical 
records for the purposes of quality assurance reviews, audits and evaluation of the study 
safety and progress.  
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstru ction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy dispen sing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photographic negatives, microfilm or magnetic media, x -rays, and subject files 
and records kept at th e pharmacy, at the laboratories, and medico -technical departments 
involved in the clinical trial.  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study case report form (CRF) is the primary data collection 
instrument for the study. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported 
on the CRF, that are de rived from source documents, should be consistent with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF 
[COMPANY_001]  Confidential  Page 78 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 should be date d, initialed, and explained (if necessary) and should not obscure the original 
entry. For electronic CRFs an audit trail will be maintained by [CONTACT_1190]. The investigator 
should retain records of the changes and corrections to paper CRFs.  
The investigator /institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
[CONTACT_64122]/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.  
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless [COMPANY_001]  provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.  
11.[ADDRESS_432897] ensure ano nymity of the patients; patients must not be identified by 
[CONTACT_64123]. Signed informed consent forms and patient 
enrollment log must be kept strictly confidential to enable patient identification at the site.  
11.8 Audits and inspections  
Source data/documents must be available to inspections by [CONTACT_5385].  
11.[ADDRESS_432898] 
be considered a protocol amendment, and unless such an amendment is agreed  upon by 
[CONTACT_6669]/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.  
12.[ADDRESS_432899] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. 
Only amendments that are required for patient safety may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal p rotocol 
amendments, the investigator is expected to take any immediate action required for the safety 
of any patient included in this study, even if this action represents a deviation from the 
protocol. In such cases, [COMPANY_001] should be notified of this ac tion and the IRB/IEC at the study 
[COMPANY_001]  Confidential  Page 79 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 site should be informed according to local regulations (e.g. [LOCATION_006] requires the notification of 
urgent safety measures within 3 days) but not later than 10 working days.  
[COMPANY_001]  Confidential  Page 80 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 13 References (available upon request)  
Amin MB (2016) AJCC  Cancer Staging System, 8th Edition: UPDATE. Creating the Bridge 
from a “Population Based” to a More “Personalized” Approach. 
https://cancerstaging.org/About/news/Documents/NCRA%20AJCC%20Cancer%20Staging%
20Manual%208th%20Edition%20Update.pdf Accessed on 07 -Nov-2016.  
Anampa J, Makover D, Sparano JA  (2015)  Progress in adjuvant chemotherapy for breast 
cancer: an overview. BMC Medicine 13:195.  
Bachelot T, Bourgier C, Cropet C, et al  (2012)  Randomized phase II trial of everolimus in 
combination with tamoxifen in  patients with hormone receptor -positive, human epi[INVESTIGATOR_33927] [ADDRESS_432900] cancer with prior exposure to aromatase 
inhibitors: a GINECO study. J Clin Oncol 30:2718 –2724.  
Beroukhim R, Mermel CH, Porter D, et al  (2010)  The landscape of somatic copy -number 
alteration across human cancers. Nature 463:899 -905. 
Bosco EE, Wang Y, Xu H, et al  (2007)  The retinoblastoma tumor suppressor modifıes the 
therapeutic response of breast cancer. J Clin Invest  117:218 -228. 
Buzdar AU  (2003)  Pharmacology and pharmacokinetics of the newer generation aromatase 
inhibitors. Clin Cancer Res. 9:468S -472S.  
Coates AS, Winer EP, Goldhirsch A, et al (2015). Tailoring therapi[INVESTIGATOR_014] – improving the 
management of early breast cancer: St Gallen International Exp ert Consensus on the Primary 
Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533 -1546  
Dawson SJ, Rosenfeld N, Caldas C. (2013) Circulating tumor DNA to monitor metastatic 
breast can cer. N Engl J Med. 369(1):[ADDRESS_432901] Cancer Trialists’ Collabora tive Group  (EBCTCG) (2005)  Effects of 
chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 -year 
survival: an overview of the randomised trials. Lancet 365:1687 –1717.  
Early Breast Cancer Trialists’ Collaborative Group  (2015)  Aromat ase inhibitors versus 
tamoxifen in early breast cancer: patient -level meta -analysis of the randomised trials. Lancet 
386:1341 –1352.  
Edevana VK, Dhakal IB, Williams S, et al  (2013)  Potential role of UGT1A4 promoter SNPs 
in anastrozole pharmacogenomics. Drug  and Metabolism Dispos 41:870 -877. 
Eggeman H, Ignatov A, Smith BJ, et al  (2013)  Adjuvant therapy with tamoxifen compared to 
aromatase inhibitors for [ADDRESS_432902] Cancer Res Treat 137:465 –
470. 
Elston, CW, and  Ellis, IO (2002) Path ologic prognostic factors in breast cancer. I. The value 
of histological grades in breast cancer. Experience from a large study with long -term follow -
up". Histopathology. 1991;19: 403 –10. Republished in Histopathology  41:154 –161. 
Esposito A, Bardelli A, Criscitiello C, et al (2014) Monitoring tumor -derived cell -free DNA 
in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat 
Rev; 40(5):648 -55. 
Fentiman IS, Fourquet A, Hortobagyi GN  (2006)  Male breast cancer. Lancet 36 7:595 –604. 
[COMPANY_001]  Confidential  Page 81 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Ferlay J, Steliarova -Foucher E, Lortet -Tieulent J, et al (2013). Cancer incidence and mortality 
patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 49:1374 -1403  
Finn RS, Dering J, Conklin D, et al  (2009)  PD 0332991, a selective cyclin D kinase 4/[ADDRESS_432903] Can Res 11:R77.  
Finn RS, Crown JP, Lang I, et al  (2015)  The cyclin -dependent  kinase 4/[ADDRESS_432904] cancer (PALOMA -1/TRIO -18): A 
randomised phase 2 study Lancet Oncol 16:25 –35. 
Finn RS, Martin M, Rugo HS, et al (2016) Palbociclib and letrozole in advanced breast cancer. 
NEJM 375:1925 -1936.  
Francis PA, Regan MM, Fleming GF, et al (2015). Adjuvant ovarian suppression in 
premenopausal breast cancer. N Engl J Med. 372:436 -446. 
Giuliano AE , Hunt KK, Ballman KV, et al  (2011)  Axillary dissection vs no axillary dissection 
in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. 
JAMA 305:569 -575. 
GLOBOCAN (2012) Estimated Cancer Incidence, Mortality and Pr evalence Worldwide 2012. 
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (assessed 17 -October -2016).  
Goetz MP, Erlichman C, Loprinzi CL, and Kohli M  (2015)  Hormonal agents. In DeVita VT, 
Lawrence TS, and Rosenberg SA “DeVita, Hellman, and Rosenberg’s  Cancer: principles & 
practice of oncology”. 10th edition. Wolters Kluwer Health.  
Goss PE, Ingle JN, Pritchard KI, et al  (2016)  Extending aromatase -inhibitor adjuvant therapy 
to 10 years. N Engl J Med 375:209 -219. 
Gradishar WJ, Anderson BO, Balassanian R, et al (2016)  Invasive Breast Cancer Version 
1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14:324 -
354. 
Grunberg SM, Warr D, Gralla RJ, et al  (2010)  Evaluation of new antiemetic agents and 
definition of antineoplastic agent em etogenicity - state of the art. Support Care Cancer  19:S43 -
S47. 
Hammond ME, Hayes DF, Dowsett M, et al  (2010)  American Society of Clinical 
Oncology/College Of American Pathologists guideline recommendations for 
immunohistochemical testing of estrogen and pr ogesterone receptors in breast cancer. J Clin 
Oncol 28:2784 –2795.  
Holm K, Staaf J, Jönsson G, et al  (2012)  Characterisation of amplification patterns and target 
genes at chromosome 11q13 in CCND1 -amplified sporadic and familial breast tumours. 
Breast Cance r Res Treat 133:583 -594. 
Hortobagyi GN, Connolly JL, D’Orsi CJ, et al  (2017) . Breast. From AJCC Cancer Staging 
Manual 8th ed. By [CONTACT_348456], Edge S, Greene FL, et al. Springer  
Hortobagyi GN, Stemmer SM, Burris HA, et al (2016) Ribociclib as first -line therapy  for HR -
positive, advanced Breast Cancer. N Engl J Med 375:1738 -1748.  
[COMPANY_001]  Confidential  Page 82 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Hoskins JM, Carey LA, McLeod HL (2009) CYP2D6 and tamoxifen: DNAA matters in 
breast cancer. Nat Rev Cancer 9:576 -586. 
Howla nder N, Noone AM, Krapcho M, et al  (2015 ) SEER Cancer Statistic s Review, 1975 -
2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based 
on November [ADDRESS_432905] EM  (2010)  Global patterns of  cancer incidence 
and mortality rates and trends. Cancer Epi[INVESTIGATOR_1948] 19:1893 –1907.  
Jeruss JS, Mittendorf EA, Tucker SL, et al  (2008)  Combined use of clinical and pathologic 
staging variables to define outcomes for breast cancer patients treat ed with neoadjuvant 
therapy. J Clin Oncol 26:246 -252. 
Lan KK, DeMets DL (1983). Discrete sequential boundaries for clinical trials. Biometrika; 
70:659 -63. 
Lipton A, Demers LM, Harvey HA, et al  (1995)  Letrozole (CGS [ZIP_CODE]). A phase I study of a 
new potent o ral aromatase inhibitor of breast cancer. Cancer. 75:2132 -2138  
Loibl S, Turner NC, Ro J, et al (2016) Palbociclib (PAL) in combination with fulvestrant (F) 
in pre -/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior 
progression on en docrine therapy – results from Paloma -3. J Clin Oncol 34 (suppl; abstr 524)  
Lyman GH, Temin S, Edge SB, et al  (2016) Sentinel lymph node biopsy for patients with 
early -stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline 
update. J Clin Oncol 32:1365 -1383.  
Mauri D, Pavlidis N, and Ioannidis  (2005)  Neoadjuvant versus adjuvant systemic treatment in 
breast cancer: a meta -analysis. JNCI J Natl Cancer Inst 97:188 -194. 
Miller TW, Balko JM, Fox EM, et al  (2011)  ERα-dependent E2F tr anscription can mediate 
resistance to estrogen deprivation in human breast cancer. Cancer Discov 1:338 -351. 
von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and Impact of Pathologic 
Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic 
Breast Cancer Subtypes J Clin Oncol. 30(15):1796 -804. 
Mittendorf EA, Jeruss JS and Tucker SL  (2011)  Validation of a novel staging system for 
disease -specific survival in patients with breast cancer treated with neoadjuvant chemotherapy . 
J Clin Oncol 15:1858 -1882.  
Murtaza M, Dawson SJ, Pogrebniak K et al (2015) Multifocal clonal evolution characterized 
using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 6:8760.  
Musgrove EA, Caldon CE, Barraclough J, et al  (2011)  Cyclin D as a therapeutic target in 
cancer. Nat Rev Cancer 11:558 -572. 
NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 2.2016 
https://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf  
Nichols M  (2015)  New directions for  drug-resistant breast cancer: the CDK4/6 inhibitors. 
Future Med Chem 12:1473 -1481.  
Plourde PV, Dyroff M, Dowsett M, et al  (1995)  Arimidex: A new oral, once -a-day aromatase 
inhibitor. J Steroid Biochem Molec Biol 53:175 -199. 
[COMPANY_001]  Confidential  Page 83 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Rizzo JD, Brouwers M, Hurley P,  et al (2010) American Society of Clinical Oncology/  
American Society of Hematology Clinical Practice Guideline update on the use of epoetin and 
darbepoetin in adult patients with cancer J Clin Oncol 33:4996 -5010  
Roila F, Molassiotis A, Herrstedt J, et al  (2016)  MASCC and ESMO Consensus Guidelines 
for the Prevention of Chemotherapy and Radiotherapy -Induced Nausea and Vomiting: ESMO 
Clinical Practice Guidelines. Ann Onc 27:v11 -v133.  
Senkus E, Kyriakides, S, Ohno S, et al  (2015)  Primary breast cancer: ESMO C linical Practice 
Guidelines for diagnosis, treatment and follow -up. Ann Oncol 26 (suppl 5): v8 -v30. 
Siegel RL, Miller KD, Jemal (2016) A Cancer statistics, 2016. CA Cancer J Clin 66:7 -30. 
Smith TJ, Bohlke K, Lyman GH, et al (2015) Recommendations for the u se of WBC growth 
factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin 
Oncol 33:3199 -3212  
Sousa B, Moser E, and Cardoso F  (2013)  An update on male breast cancer and future 
directions for research and treatment. Eur J Pha rmacol 71:771 –783. 
Thangavel C, Dean JL, Ertel A, et al  (2011)  Therapeutically activating RB: reestablishing cell 
cycle control in endocrine therapy -resistant breast cancer. Endocr Relat Cancer 18:333 -345. 
The Cancer Genome Atlas Network  (2012)  Comprehensi ve molecular portraits of human 
breast tumours. Nature 490:61 -70. 
Torre LA, Bray F, Siegel RL et al  (2015)  Global cancer statistics, 2012. CA Cancer J Clin 
65:87 –108. 
Tripathy D, Sohn J, Im SA, et al  (2017) .  First-line ribociclib vs placebo with goserelin  and 
tamoxifen or a non -steroidal aromatase inhibitor in premenopausal women with hormone 
receptor -positive, HER2 -negative advanced breast cancer: results from the randomized phase 
III MONALEESA -7 trial. Presented at: the [ADDRESS_432906] Cancer Sym posium; 
Abstract GS2 -05.  
Trunet PF, Bhatnagar AS, Chaudri HA, et al  (1996)  Letrozole (CGS20267) a new oral 
aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. 
Acta Oncol 35S5:15 -18 
Turner NC, Ro K, Andre F  (2015)  Palbociclib in Hormone -Receptor -Positive Advanced 
Breast Cancer. N Engl J Med. 373:209 -219. 
  
[COMPANY_001]  Confidential  Page 84 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 14 Appendices  
14.1 Appendix 1:  Guidelines for Anatomic and Prognostic Stage 
Group III of HR -positive, HER2 -negative Breast Cancer for breast 
cancer staging (based on AJCC Ed. 8th) 
Guidelines for anatomic and prognostic stage groups according to AJCC Ed. 8th applicable to 
this study are presented in Table 14 -1 and Table 14-2 below  (modified from Hortobagyi et al 
2017 ). 
Table 14-1 AJCC 8th edition Anatomic Stage Groups ( not including Group IV - all 
M-category M0)  
Anatomic Stage Group  T-category  N-category  
[ADDRESS_432907] Cancer (all M -category M0)  
T-category  N-category  Grade  ER Status  PR Status  
Prognostic Stage Group IIIA  
T0-1 N1 3 Positive  Negative  
T0-1 N1 3 Negative  Positive  
T2* N0 3 Positive  Negative  
T2 N0 3 Negative  Positive  
T2 N1 1 or 2  Positive  Negative  
T3 N0 1 or 2  Positive  Negative  
T0-2 N2 1  Positive  Negative  
T0-2 N2 1  Negative  Positive  
T3 N1-2 1 Positive  Negative  
T3 N1-2 1 Negative  Positive  
T4 N0-2 1 Positive  Positive  
Any N3 1 Positive  Positive  
[COMPANY_001]  Confidential  Page 85 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 T-category  N-category  Grade  ER Status  PR Status  
Prognostic Stage Group IIIB  
T2 N1 3 Positive  Negative  
T3 N0 3 Positive  Negative  
T0-2 N2 2 Positive  Negative  
T0-2 N2 2 Negative  Positive  
T0-2 N2 3 Positive  Positive  
T3 N1-2 2 Positive  Negative  
T3 N1-2 2 Negative  Positive  
T3 N1-2 3 Positive  Positive  
T4 N0-2 2 Positive  Positive  
Any N3 2 Positive  Positive  
Prognostic Stage Group IIIC  
T2 N1 3 Negative  Positive  
T3 N0 3 Negative  Positive  
T0-2 N2 3 Positive  Negative  
T0-2 N2 3 Negative  Positive  
T3 N1-2 3 Positive  Negative  
T3 N1-2 3 Negative  Positive  
T4 N0-2 1 or 2 or 3  Positive  Negative  
T4 N0-2 1 or 2 or 3  Negative  Positive  
T4 N0-2 3 Positive  Positive  
Any N3 1 or 2 or 3  Positive  Negative  
Any N3 1 or 2 or 3  Negative  Positive  
Any N3 3 Positive  Positive  
*If Oncotype Dx® was performed and the recurrence score is less than 11, then T1 -2, N0, grade 1 -3 patients 
would be considered to be Prognostic Group IA  
[COMPANY_001]  Confidential  Page 86 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 14.2 Appendix 2: Concomitant medications  
In general, the use of any concomitant medication deemed necessary for the care of the patient 
is permitted in this study, except as specifically prohibited below. Combination administration 
of study drugs could result in drug -drug interactions (DDI) that could potentially lead to 
reduced activity or enhanced toxicity of the concomitant medication and/or ribociclib . 
The following lists are based on the Oncology Clinical Pharmacology Drug -Drug Interaction 
and Co -Medication Considerations  (v06 release date: 2 016), which was compi[INVESTIGATOR_283566]’s “Clinically Relevant” Table 
(medicine.iupui.edu/clinpharm/ddis/main -table/ ) and supplemented with the FDA Draft 
Guidance for Indu stry, Drug Interaction Studies - Study Design, Data A nalysis, and 
Implications for Dosing and Labeling (February 2012) 
(fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.p
df), and the University of Washington’s Drug Interaction Database ( druginteractioninfo.org/ ). 
For current lists of medications that may cause QT prolongation and/or Torsades de Pointes 
(TdP), refer to the CredibleMeds® website (qtdrugs.org/).  
These lists are not comprehensive and are only meant to be used as a guide. Please contact [CONTACT_348457].  
Table 14-[ADDRESS_432908] of prohibited medications during study drug treatment  
Category  Drug Name  
[CONTACT_15105]3A4/5 inhibitors  VIEKIRA PAK2, indinavir/ritonavir, tipranavir/ritonavir, ritonavir, cobicistat (GS -
9350), indinavir, ketoconazole, troleandomycin, telaprevir, danoprevir/ritonavir, 
elvitegravir/ritonavir, saquinavir/ritonavir, lopi[INVESTIGATOR_054]/ritonavir, itraconazole, 
voriconazole, mibefradil , clarithromycin, posaconazole, telithromycin, 
grapefruit juice, conivaptan, nefazodone, nelfinavir, saquinavir, idelalisib, 
boceprevir, darunavir/ritonavir  
Strong CYP3A4/5 inducers  Avasimibe2,3, carbamazepi[INVESTIGATOR_050], enzalutamide,  mitotane, phenobarbital, 
phenytoin, rifabutin, rifampin (rifampi[INVESTIGATOR_2513])3, St. John's wort (hypericum 
perforatum)3 
CYP3A substrates with NTI1 Alfentanil, api[INVESTIGATOR_3822] (doses >2.5 mg only), aprepi[INVESTIGATOR_053], astemizole, cisapride, 
cyclosporine, diergotamine (dihydroerg otamine), ergotamine, fentanyl, 
lovastatin, nicardipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], pi[INVESTIGATOR_3924], quinidine, rivaroxaban, 
simvastatin, sirolimus, tacrolimus, terfenadine , thioridazine , lomitapi[INVESTIGATOR_348400] a known risk 
for QT prolongation4 Amiodarone, anagrelide, arsenic trioxide, astemizole, azithromycin, 
chloroquine, chlorpromazine, cilostazol, ciprofloxacin, cisapride, citalopram, 
clarithromycin, cocaine,  disopyramide, dofetilide, domperidone, donepezil, 
dronedarone, droperidol, erythromycin, escitalopram, flecainide, fluconazole, 
halofantrine, haloperidol, ibutilide, levofloxacin, levomethadyl, mesoridazine, 
methadone, moxifloxacin, ondansetron (i.v. only),  oxaliplatin , papaverine HCl 
(intra -coronary) , pentamidine, pi[INVESTIGATOR_3924], procainamide, propofol, quinidin e, 
sevoflurane, sotalol,   sulpi[INVESTIGATOR_14956], terfenadine, thioridazine, vandetanib  
Herbal preparations/ 
medications  Herbal preparations/medications known as strong  inducers or inhibitors of 
CYP3A 4/5 are prohibited throughout the study. These herbal medications 
include, but are not limited to: St. John’s wort, Kava, ephedra (ma huang), 
gingko biloba, dehydroepi[INVESTIGATOR_2119] (DHEA), yohimbe, saw palmetto, and 
ginseng. Patients should stop using these herbal medications [ADDRESS_432909] dose of study drug.  
[COMPANY_001]  Confidential  Page 87 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Category  Drug Name  
[CONTACT_348461] r investigational and anti -
neoplastic therapi[INVESTIGATOR_348401]. Anti -neoplastic  therapy (chemotherapy, biologic or radiation therapy, 
and surgery) other than the study treatments must not be given to patients 
while the patient is on the study treatment . If such agents are required for a 
patient then the patient must  discontinue study  drug.  
1 NTI = narrow therapeutic index drugs whose exposure -response indicates that increases in their exposure levels 
by [CONTACT_64128] (e.g., Torsades de Pointes).  
[ADDRESS_432910]  
3 P-gp in ducer  
4 Source: qtdrugs.org (as of March  2, 2018) 
As far as possible, avoid co -administration of QT prolonging drugs or any other drugs with the potential to 
increase the risk of drug -related QT prolongation (e.g., via a potential DDI that increases the ex posure of ribociclib 
or the exposure of the QT prolonging drug). A definitive list of drugs with a known risk, possible risk, or conditional 
risk of QT prolongation and/or Torsades de Pointes (TdP) is available online at qtdrugs.org.  
Table 14-[ADDRESS_432911] of medications to be used with caution during study drug 
treatment  
Category  Drug Name  
[CONTACT_15106]3A4/5 inhibitors  Amprenavir, atazanavir, casopi[INVESTIGATOR_053], cimetidine, darunavir, diltiazem, 
fosamprenavir netupi[INVESTIGATOR_053], tofisopam, verapamil , crizotinib, faldaprevir, imatinib, 
nilotinib  
Moderate CYP3A4/5 inducers  Bosentan, efavirenz, etravirine, genistein, lersivirine, modafinil, nafcillin, 
talviraline , semagacestat, lopi[INVESTIGATOR_348402]3A4/5 
substrates1 Alpha -dihydroergocryptine, alisoporivir,  almorexant, aplaviroc, api[INVESTIGATOR_3822] (doses 
< 2.5 mg only), atazanavir, atorvastatin, avanafil, bosutinib, brecanavir, 
brotizolam , budesonide, buspi[INVESTIGATOR_5331], capravirine, casopi[INVESTIGATOR_053], 
danoprevir, darifenacin, darunavir, dasatinib,  ebastine, eletriptan, elvitegravir,  
eplerenone,  everolimus,  felodipi[INVESTIGATOR_050], fluticasone, ibrutinib, ivacaftor,  lumefantrine, 
lurasidone, maraviroc, midazolam, midostaurin, naloxegol,  neratinib,  
perospi[INVESTIGATOR_5331], quetiapi[INVESTIGATOR_050], ridaforolimus, sildenafil, simeprevir,  ticagrelor,  tilidine,  
tipranavir,  tolvaptan, triazolam,  ulipristal , vardenafil, vicriviroc, voclosporin  
Strong BSEP inhibitors  Alectinib, atazanavir , bromoc riptine, Bosentan,  clofaziminie, cerivastatin,  
fusidate, glibenclamide,  glyburide, nefazadone, paritaprevir, pi[INVESTIGATOR_051], 
reserpi[INVESTIGATOR_050], rosiglitazone,  sulindac, troglitazone (TGZ -sulfate) , valinomycin  
Medications that carry a 
possible risk for QT 
prolongati on2 Alfuzosin, apomorphine, aripi[INVESTIGATOR_4253], artenimol+pi[INVESTIGATOR_14961],  atazanavir, 
atomoxetine, asenapi[INVESTIGATOR_050], bedaquiline, bortezomib, buprenorphine, capecitabine, 
ceritinib, clomipramine, crizotinib, clozapi[INVESTIGATOR_050], cyamemazine (cyamepromazine), 
dabrafenib, dasatinib,  degarilix, delamanid, desipramine,  dexmedetomidine, 
dolasetron, eribulin, ezogabine,  famotidine, felbamate, fingolimod, foscarnet, 
gatifloxacin, gemifloxacin, granisertron, hydrocodone -ER, iloperidone, 
imipramine (melipramine),  isradipi[INVESTIGATOR_050], lapatinib, lenvatinib, leuprolide,  
loperamide , lithium,  metolazone,  mifepristone , mirabegron, mirtazapi[INVESTIGATOR_050], 
moexipril, norfloxacin, nortriptyline,  ofloxacin, olanzapi[INVESTIGATOR_050], osimertinib , 
ondansetron ( p.o. only at 4 mg or 8 mg),  oxytocin, paliperidone, panabinostat,  
pasireotide, pazopanib,  pi[INVESTIGATOR_14964], promethazine, propafenone,  quetiapi[INVESTIGATOR_050], 
ranolazine, rilpi[INVESTIGATOR_12979], risperidone, roxithromycin, sertindole, sorafenib, sunitinib,  
telavancin, tetrabenazine,  tizanidine, tolterodine, toremifene, tramadol,  
trimipramine,  varde nafil, vemurafenib,  venlafaxine,  vorinostat, ziprasidone  
MATE1 and OCT2 substrates3 Acyclovir, amantadine, amiloride, apricitabine, carboplatin, cisplatin,  cephalexin, 
cephradine, cimetidine, dofetilde,  famotidine, fexofenadine, furamidine, 
ganciclovir, glycopyrronium, Ipratropi[INVESTIGATOR_1890], lamivudine,  linagliptin, memantine, 
metformin (also a substrate for OCT1, MATE1, and MATE2K), oxyplatin,  
pi[INVESTIGATOR_8405], plisicainide,  pramsorafenib,  ranitidine, topotecan , tropi[INVESTIGATOR_14960], trospi[INVESTIGATOR_1890], 
umeclidinium, varencicline , zidovudin e 
[COMPANY_001]  Confidential  Page 88 
Amended Protocol Version 02 (Clean)   Protocol No. CLEE011G2301  
 
 Category  Drug Name  
[CONTACT_348462], doxorubicin, ethinyl estradiol methotrexate, mitoxantrone, 
pi[INVESTIGATOR_2830] , rosuvastatin, sulfasalazine , sofosbuvir, tenofovir  
1 Sensitive substrates: Drugs whose plasma AUC values have been shown to increase 5 -fold or higher when co -
administered with a potent inhibitor.  
2 Source: qtdrugs.org (as of March  02,, 2018) 
3 Source: FDA Draft Guidance for Industry, Drug Interaction Studies – Study Design, Data Analysis, and 
implications for Dosing and Labeling (February 2012) and Yonezawa and Inui (2011) Importance of the multidrug 
and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and 
pharmac ogenomics. Br J Pharmacology 164:1817 -25; www.druginteractioninfo.org  (as of May, 2016)  
 